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ABSTRACT OF THE DISSERTATION 
Investigation of the Contribution of Type 1 Pili in Enterotoxigenic Escherichia Coli 
(ETEC) Pathogen-Host Interactions 
By 
Alaullah Sheikh 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Microbiology and Microbial Pathogenesis 
Washington University in St. Louis, 2017 
Professor James M Fleckenstein, Chair 
 
Enterotoxigenic Escherichia coli (ETEC) are one of the leading causes of death due to 
diarrhea in children living in developing countries. ETEC are also the leading cause of 
diarrhea in travelers to developing countries lacking sanitation and safe drinking water. 
Unfortunately, there is no broadly protective vaccine available against these important 
pathogens. In order to cause infection, ETEC colonize the intestinal epithelium and 
secrete toxins, including heat-labile toxin (LT) and/or heat-stable toxin (ST). Efficient 
delivery of these toxins to the cognate receptors on target intestinal cells requires direct 
ETEC-host interactions. Earlier studies demonstrated that ETEC facilitate interactions 
with host by pathotype specific adhesive pili, termed as colonization factor (CF). 
However, recent studies demonstrate that in order to establish interactions with host, 
ETEC engage multiple factors, including number of ETEC-specific virulence factors as 
well as factors those are highly conserved across different E. coli.  
ix 
Detection of increased expression of type 1 pili encoding genes from cell adherent 
ETEC led to the hypotheses that these pili facilitate ETEC adhesion to intestinal 
epithelial cells and promote delivery of toxins to target cells. Using polarized culture of 
intestinal cell lines as well as human ileal enteroids, we observe that FimH adhesin of 
type 1 pili facilitate ETEC adhesion, antibody mediated or chemical inhibition of FimH 
interaction decrease ETEC adhesion and increased expression of highly mannosylated 
glycoprotein receptor of FimH enhance ETEC adhesion to host. Additionally, we find 
that FimH interactions augment delivery of toxins and are required for virulence, as we 
detect reduced fluid accumulation by fimH mutant in the rabbit ileal loop assays, a 
standard model of ETEC pathogenesis.  
Although earlier studies reported that LT enhances ETEC-host interactions, the 
underlying enhancement mechanism is undefined. Using RNAseq and mass 
spectrometric analysis we demonstrate that LT enhances glycoprotein synthesis and 
increases surface presentation high mannose glycans. Additionally, LT increases 
expression of CEACAM6 receptor of FimH adhesin on intestinal epithelial cells. 
Interestingly, deletion of FimH-CEACAM6 interactions decreased ETEC adhesion to 
host, identifying a novel ETEC-host interaction. However, in contrast to the contribution 
of FimH in adhesion, deletion of FimH activity increased colonization of mice by ETEC. 
Interestingly, we detected increased expression of several adhesion related factors, 
including PqiB, a homologue of Mam7 adhesin, by fimH mutant recovered from mice, 
signifying the importance of functionally complementary adhesins of ETEC. Together, 
x 
these findings propose a mechanistic explanation of LT-mediated enhancement of 
ETEC adhesion, and identify a novel ETEC-host interaction. 
Collectively, data presented in the thesis demonstrate the contribution of type 1 pili in 
ETEC pathogenesis, notice previously unidentified FimH-CEACAM6 interactions of 
ETEC and identify a highly conserved putative Mam7 adhesin that may facilitate 
intestinal colonization by ETEC. Overall, these findings expand our understanding of 
ETEC pathogenesis and could supplement rational approach to broadly protective 
ETEC vaccine design. 
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CHAPTER ONE 
Introduction: Type 1 pili in enterotoxigenic Escherichia coli infection 
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1.1 Global burden of enterotoxigenic Escherichia coli infections 
More than 1 billion people are deprived of clean water (1) and 1 in every 3 people does 
not have access to even minimal sanitation (2). Consequently, acute diarrheal illness, 
mostly caused by ingestion of food and drink contaminated with pathogens transmitted 
via the fecal-oral route, is a leading cause of mortality and morbidity in children (3). In 
fact, it is the second leading cause of death in children under five years old (4), resulting 
more than 700000 deaths every year (5). Of the different causes, enterotoxigenic 
Escherichia coli (ETEC) are among major bacterial pathogens associated with severe 
diarrheal illness in children (6). ETEC are one of the major pathotypes of diarrheagenic 
E. coli, and are characterized by the production of heat labile (LT) and/or heat stable 
(ST) enterotoxins. Children less than 5 years of age, living in resource poor countries 
with compromised hygiene and sanitation, are particularly vulnerable to ETEC infections 
(7, 8). ETEC diarrhea is a leading cause of childhood morbidity and contributes 
substantially to delayed growth and development and malnutrition (9-11), which in turn 
increases the risk of repetitive diarrhea (12). ETEC also induce acute watery diarrhea in 
adults that can be severe and cholera-like requiring hospitalization (13).  
Additionally, ETEC are frequently isolated pathogens in travelers with acute diarrhea. 
Travelers, including military personnel, from developed countries are at high risk of 
travelers’ diarrhea when they visit countries with inadequate sanitation and safe drinking 
water. According to the U.S. Centers for Disease Control and Prevention around 10 
million travelers get diarrhea each year (14, 15) and depending on the destination and 
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type of travel an attack rate of 29 cases per every 100 person-months was estimated by 
U.S. military (16).  
Contaminated food represents another important vehicle of transmission for pathogens. 
Globalization of the food supply, which may inadvertently introduce pathogens to 
developed countries (17), poses a threat of foodborne diseases. In fact, every year, an 
estimated 1 in 6 Americans get sick from foodborne illness (18). Unfortunately, there 
have been a number of substantial ETEC outbreaks in the United States associated 
with contaminated food (19-23). Moreover, symptomatic and asymptomatic carriers 
including travelers, refugees and immigrants from developing countries may introduce 
these pathogens to developed countries (24), resulting in unavoidable emergence of 
ETEC pathogens in these regions (21-23, 25). Therefore, although endemic in the 
resource poor settings, ETEC infections present a global public health burden. 
1.2 Enterotoxigenic Escherichia coli pathogenesis 
Adhesion to the intestinal epithelial cells is critical for ETEC to become established at 
the site of infection (26) and for effective delivery of different effector molecules (27) that 
may modulate host responses. Several studies have demonstrated that the effective 
toxin delivery requires close association of bacteria to the host cell (27, 28). 
Interestingly, host cell contact was recently shown to modulate a variety of known and 
putative virulence genes (29, 30). Classically, ETEC deploy fimbrial virulence structures, 
known as colonization factors (CFs) for attachment to the intestinal epithelium (31). CF 
fimbriae are plasmid-encoded and both antigenically and structurally diverse. ETEC 
express more than 26 different CFs and an isolate may express one or multiple CFs on 
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the surface (31). Although CFs are important virulence factors, multiple studies reported 
that about half of the ETEC strains do not possess an identifiable CF (31, 32). Recent 
pathogenesis studies also suggest that these organisms require multiple virulence 
factors to effectively engage target intestinal epithelial cells and deliver toxins (33). 
These include at least two proteins with mucinase activity, including EatA and YghJ, 
which degrade intestinal mucin (34, 35), and EtpA, a novel secreted adhesin that binds 
to both the tip of the flagellum (36) and to the MUC-2 mucin (37), thereby acting as a 
molecular bridge between ETEC flagella and the host cell surface.  
The biology of the toxins produced by ETEC has been defined in some detail. LT is an 
AB5 enterotoxin consisting of pentameric B subunit (LT-B) and a single A subunit (LT-A) 
(38). Both monomeric LT-B and LT-A translocate to the bacterial periplasm via Sec 
machinery where LT-B molecules pentamerize and associate with LT-A to form the 
heterohexameric holotoxin. LT holotoxin is secreted across the outer membrane via a 
functional Type II secretion apparatus (39). The pentameric B subunit binds to GM1 
ganglioside on the cell surface, triggering cellular uptake of the toxin. Following 
endocytosis, the catalytic LT-A subunit translocates through the vacuolar membrane 
and passes to the endoplasmic reticulum through the Golgi apparatus by retrograde 
transport and is activated by proteolytic cleavage (40). Once inside the cell, LT-A ADP-
ribosylates the alpha subunit of G protein, a guanine nucleotide-binding protein that 
activates the catalytic unit of adenylyl cyclase (AC), resulting in permanent activation of 
AC (41, 42) and subsequent increases in intracellular cAMP (43). Increased cAMP in 
turn activates protein kinase A (PKA) resulting in phosphorylation of apical membrane 
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transporters (especially the cystic fibrosis transmembrane conductance regulator, 
CFTR), thereby promoting secretion of anions (Cl- and HCO3
-) by crypt cells and a 
decrease in absorption of Na+ and Cl- by absorptive cells (43). ST is a small monomeric 
toxin with multiple disulfide bonds, accounting for the heat stability of the toxin. Mature 
ST is either a 18-amino-acid peptide known as STp/ST1a, mostly present in porcine 
ETEC, or a 19- amino-acid peptide known as STh/ST1b, mostly present in human 
ETEC (44). ST is synthesized as precursor protein and translocated across the inner 
membrane via the Sec machinery (45), and subsequently through the outer membrane 
via TolC (46). Secreted ST molecules bind to the extracellular receptor domain of 
guanylyl cyclase C (GC-C) on the brush border of intestinal epithelium. These 
interactions activate the intracellular catalytic domain of GC-C, resulting in accumulation 
of intracellular cGMP and subsequent  activation of cGMP-dependent protein kinase II, 
which leads to phosphorylation of the CFTR, and consequent chloride secretion (43). In 
addition, enhanced cGMP also inhibit activity of Na+/H+ exchangers (NHEs), resulting 
decreased fluid absorption (47, 48).  
Since LT and ST toxins eventually induce excessive fluid loss with ensuing diarrhea, 
factors that influence secretion and/or delivery of these toxins ultimately affect virulence. 
Emerging evidence supports the concept that ETEC pathogenesis is more complicated 
than previously appreciated, and that optimal toxin delivery to target cells requires 
orchestrated involvement of multiple virulence factors. Interruption of any of the 
corresponding activities potentially abrogates toxin delivery and reduces ETEC 
virulence (33, 49). In order to investigate the genes that are involved in ETEC-host 
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interactions, we infected Caco-2 intestinal cells with ETEC and compared the 
transcriptome of cell associated ETEC with planktonic ETEC (29). This study identified 
multiple genes that are differentially regulated in cell associated ETEC, including 
increased transcription of genes that are involved in type 1 pili biogenesis (50), 
suggesting a potential role for these pili in ETEC-host interactions.   
1.3 Type 1 pili 
Type 1 pili are heteromeric fiber like structures, made up of a helical rod comprised of a 
major structural subunit polymer, FimA, joined to a tip consisting of three minor 
subunits, including FimF, FimG and FimH (51-53). These pili are encoded on the 
chromosome in the fim operon (54), and are expressed by both commensal and 
pathogenic E. coli (55). Type 1 pili are one of the most extensively studied chaperone-
usher pathway (CUP) pili. The molecular detail of type 1 pili assembly has been 
described, outlining a paradigm for CUP pili biogenesis (53). Assembly of type 1 pili 
requires at least nine genes (Fig 1a), including fimB and fimE genes encoding two 
recombinases which control the pili biogenesis (56) by regulating expression of the 
major structural subunit encoding gene fimA. fimC and fimD genes encode the 
chaperone-usher export system which guides the folding and assembly of different 
subunits and translocates the pilus rod outside the cell as it polymerizes (Fig 1b). The 
fimF, fimG and fimH genes encode minor structural subunits which form the distal end 
of the pili where the FimH adhesin is positioned at the tip (52).  
The invertible switch element that allows the promoter either in ‘ON phase’ orientation to 
drive transcription of fimA or in ‘OFF phase’ orientation to prevent fimA transcription 
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(57), permits bacteria to switch between piliated and nonpiliated states (56, 58). Of the 
two recombinases that control the switching between ON and OFF phases (59, 60), 
FimB recombinase inverts the switch element in both ON to OFF phase and OFF to ON 
phase orientations favoring pilus formation (61). On the other hand, FimE recombinase 
mediated inversion is biased towards ON to OFF phase orientation which stops pilus 
formation, resulting in nonpiliated bacteria (60, 61).  Additionally, for efficient inversion 
of the switch element, both FimB and FimE require multiple accessory regulators, 
including the leucine-responsive regulatory protein (Lrp), the integration host factor 
(IHF), and the nucleoid-associated protein H-NS global regulators (61-63). Therefore, 
any factors that influence expression of FimB and FimE recombinases and/or the 
accessory regulators may affect type 1 pili formation. Consequently, type 1 pili 
expression is affected by different biological as well as environmental signals including 
temperature, culture conditions, and media composition (59, 60, 64). For instance, static 
broth culture favors type 1 pili expression, whereas growth of E. coli  on agar favors 
nonpiliated bacteria (65). Similarly, E. coli growth at 28˚C cease type 1 pili expression 
yielding nonpiliated bacteria, whereas E. coli growth at 37˚C promotes type 1 pili 
expression (64). These complex sensory inputs may permit the bacteria to assess the 
appropriate niche for type 1 pili expression. For instance, 37˚C (body temperature) and 
neutral pH of human small intestine, which favor type 1 pili expression (61, 64), would 
allow E. coli to shift toward fimbriated state and promote their adhesion and colonization 
of small intestinal epithelia. Therefore, the multi-tier control of type 1 pili expression, by 
sensing both intrinsic and extrinsic factors, helps E. coli to express these adhesion 
molecules in an appropriate niche.  
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1.4 Type 1 pili in pathogen-host interactions 
Bacterial attachment to the host is mediated by specific interactions between molecules 
on the surface of bacteria and the target receptors on the host tissues. E. coli possess a 
large number of CUP pili (66) that present the adhesin molecules to facilitate bacteria-
host interactions. Although CUP pili utilize a general mechanism of biogenesis, each 
pilus operon comes with its native regulatory system as well as chaperone-usher 
system (66), suggesting that these operons might sense specific signal(s) for 
expression. For example, uropathogenic E. coli (UPEC) strains that cause acute 
pyelonephritis mostly express P-pili, another CUP pili which interacts with globoseries 
glycosphingolipids of human kidney cells (67, 68), while UPEC strains that cause 
cystitis mostly express type 1 pili which interact with mannosylated uroplakin of 
uroepithelium (69, 70). Additionally, in some cases both CUP pili, p pili and type 1 pili, 
might act in synergy for efficient pathogen-host interactions (71).  
Type 1 pili have been reported as a major virulence factor for UPEC pathogenesis (72). 
These pili are important for multiple stages of UPEC pathogenesis, including attachment 
and invasion of uroepithelial cells (73, 74) and intracellular bacterial community 
formation (75). Type 1 pili are also a purported virulence factor for other pathogenic E. 
coli, including adherent-invasive E. coli (AIEC) that have been associated with Crohn’s 
disease (CD) (76, 77). In CD patients, type 1 pili of AIEC recognize a highly 
mannosylated glycoproteins, carcinoembryonic antigen like cell adhesion molecule 6 
(CEACAM6), which is present in excess on the intestinal epithelium of these patients 
(77-79). Therefore, pathogenic E. coli might utilize type 1 pili depending on the 
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environmental cues they sense in different niche, in facilitating specific bacteria-host 
interactions. 
Since the FimH adhesin of type 1 pili is a mannose binding lectin, it can recognize a 
wide range of glycoconjugates carrying mannose structures, offering a broad binding 
range for interactions. Consequently, FimH has been shown to interact with myriad of 
host cells, including bladder and kidney epithelial cells (75), buccal cells (80), 
erythrocytes (81), mast cells (82), neutrophils (83), macrophages (84) as well as 
intestinal epithelial cells (79, 85). Additionally, FimH of type 1 pili bind to mannosylated 
proteins of Yeast causing agglutination (86). In order to facilitate these interactions, the 
FimH adhesin binds to a range of host molecules, including uroplakins (69), integrins 
(87), laminin (88), Tamm–Horsfall protein (89), CD48 (84), collagens (88), Toll Like 
Receptor 4 (TLR4) (90) and CEACAMs (85).  Multiple studies have demonstrated that 
inhibition of FimH mediated interactions by anti-FimH antibodies (91) or by soluble D-
mannose or mannosides (92, 93) as well as by a number of naturally occurring 
compounds containing terminal mannose residues (94-96) reduce pathogenesis, 
suggesting that these interactions are essential for the pathogenesis of many E. coli 
(78, 93, 97). Accordingly, type 1 pili are an important therapeutic target against 
pathogens that engage these pili in interactions with host.  
1.5 Type 1 pili in ETEC 
Although type 1 pili are important virulence factor for UPEC pathogenesis (72, 97) and 
the fim operons of UPEC and ETEC are virtually identical, their role in ETEC 
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pathogenesis has not been investigated. ETEC make type 1 pili that are distinct from 
the plasmid-encoded CFs (26, 98). The potential contribution of type 1 pili to ETEC 
adhesion was first suggested many years ago (98-100), and early attempts to use crude 
preparations of ETEC type 1 pili (then referred to as somatic fimbriae) in vaccines gave 
mixed results (99). While many recent studies identified multiple plasmid encoded novel 
virulence factors (35, 37, 49, 101), several studies suggested that chromosomally 
encoded type 1 pili may also be involved in ETEC pathogenesis (26, 98, 100). 
Nevertheless, recent demonstrations that type 1 pili encoding genes are up-regulated 
on cell contact (29) prompted a reexamination of their potential role in ETEC 
pathogenesis. Moreover, LT induces many changes in target epithelial cells, including 
mucin glycoprotein synthesis and secretion (37, 102), which might impact type 1 pili 
mediated pathogen-host interactions (103). Since type 1 pili encoding genes are part of 
the E. coli core genome, we speculate the presence of these genes in majority of the 
ETEC strains. Therefore, understanding the role of these pili might update our 
understanding of ETEC pathogenesis and determine whether type 1 pili mediated 
ETEC-host interactions are effective targets for broadly protective ETEC vaccines. 
1.6 Hypotheses 
Recently we observed significant induction of fim genes in ETEC H10407, a well 
characterized clinical isolate used in most of the ETEC pathogenesis studies, which 
were bound to intestinal epithelial cells. Additionally, deletion of the pilin subunit 
encoding fimA gene in H10407 eliminated mannose specific interactions, detected by 
the loss of yeast agglutination activity, a widely used assay for type 1 pili mediated 
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mannose specific interactions (Fig 2a). These observations suggested that type 1 pili 
are the only source of mannose specific interactions demonstrated by ETEC H10407. 
Moreover, fimA mutants were significantly less adherent than the wild type H10407 
(WT) (Fig 2b) and methyl-α-D-mannose demonstrated significant inhibition of H10407 
adhesion (not shown), comparable to fimA mutants, to Caco-2 intestinal cells. These 
observations and a report from earlier study (104) suggested that the mannose specific 
inhibition of ETEC adhesion is probably attributed to type 1 pili.  
While ETEC make type 1 pili and the genes involved in the biogenesis of these pili are 
induced in contact with target epithelial cells, the contribution of these pili in ETEC 
pathogenesis has never been thoroughly investigated. Since earlier studies reported 
that intimate interaction with the host is essential for delivery of enterotoxins to the 
epithelial cells, type 1 pili mediated ETEC-host interactions might contribute significantly 
in the pathogenesis process. Therefore, we hypothesized that type 1 pili of ETEC may 
facilitate interactions with the host which promote toxin delivery to target epithelial cells. 
In order to test this hypothesis, we had following specific aims: 
1) Investigate the role of type 1 pili in mediating adhesion of ETEC to the host 
intestinal epithelial cells and determine whether these structures are essential for 
the delivery of the ETEC enterotoxins. 
2) Examine whether LT-induced changes in epithelial cells impact type 1 pili 
mediated ETEC-host interactions.  
3) Investigate the contribution of type 1 pili in ETEC colonization to the intestinal 
epithelium.   
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CHAPTER ONE: FIGURES 
Figure 1. Biogenesis of type 1 pili. 
a) Genes present in the fim operon. b) Schematic diagram of type 1 pili biogenesis (52, 
53). Structural subunits are translocated to the periplasm via general secretory pathway, 
where the chaperone (FimC) guide their folding and transfer to the usher (FimD). Minor 
subunits, including FimF, FimG and FimH form the tip where FimH is located at the 
distal end, and the major structural subunit (FimA) polymerizes to form the pilus rod.   
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Figure 2. Type 1 pili mediated interactions of ETEC. 
a) Yeast agglutination (YA) assays demonstrating type 1 pili specific interactions of 
ETEC with Baker’s yeast. While deletion of fimA diminished YA activity, 
complementation of the mutant by episomal expression of FimA (pfimA) restored YA 
activity. b) Type 1 pili mediated adhesion to Caco-2 intestinal cells. The percentage of 
cell associated bacteria represents the portion of bacteria associated with the CIE at the 
end of 1 h relative to the inoculums. Bars represent mean values ± SEM of 5 replicates. 
P values were calculated by nonparametric Mann-Whitney test. 
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CHAPTER TWO 
Highly conserved type 1 pili promote enterotoxigenic E. coli pathogen-host 
interactions 
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ABSTRACT 
Enterotoxigenic Escherichia coli (ETEC), defined by their elaboration of heat-labile (LT) 
and/or heat-stable (ST) enterotoxins, are a common cause of diarrheal illness in 
developing countries. Efficient delivery of these toxins requires ETEC to engage target 
host enterocytes. This engagement is accomplished using a variety of pathovar-specific 
and conserved E. coli adhesin molecules as well as plasmid encoded colonization 
factors. Some of these adhesins undergo significant transcriptional modulation as ETEC 
encounter intestinal epithelia, perhaps suggesting that they cooperatively facilitate 
interaction with the host. Among genes significantly upregulated on cell contact are 
those encoding type 1 pili. We therefore investigated the role played by these pili in 
facilitating ETEC adhesion, and toxin delivery to model intestinal epithelia. We 
demonstrate that type 1 pili, encoded in the E. coli core genome, play an essential role 
in ETEC virulence, acting in concert with plasmid-encoded pathovar specific 
colonization factor (CF) fimbriae to promote optimal bacterial adhesion to cultured 
intestinal epithelium (CIE) and to epithelial monolayers differentiated from human small 
intestinal stem cells. Type 1 pili are tipped with the FimH adhesin which recognizes 
mannose with stereochemical specificity.  Thus, enhanced production of highly 
mannosylated proteins on intestinal epithelia promoted FimH-mediated ETEC adhesion, 
while conversely, interruption of FimH lectin-epithelial interactions with soluble 
mannose, anti-FimH antibodies or mutagenesis of fimH effectively blocked ETEC 
adhesion. Moreover, fimH mutants were significantly impaired in delivery of both heat-
stable and heat-labile toxins to the target epithelial cells in vitro, and these mutants were 
substantially less virulent in rabbit ileal loop assays, a classical model of ETEC 
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pathogenesis. Collectively, our data suggest that these highly conserved pili play an 
essential role in virulence of these diverse pathogens. 
AUTHOR SUMMARY 
Enterotoxigenic Escherichia coli (ETEC) infections contribute substantially to death and 
morbidity due to diarrheal illness and are associated with serious sequelae including 
malnutrition, stunted growth, and intellectual impairment among young children in 
developing countries. Effective engagement of intestinal epithelial cells is essential for 
ETEC pathogenesis. Consequently, pathovar specific plasmid-encoded adhesin 
structures known as colonization factors (CFs) have been a principal target for 
vaccines. However, tremendous inter-strain variation in the carriage of gene clusters 
encoding different CFs and significant antigenic diversity of the CF adhesins has posed 
a challenge to vaccine development. In contrast, type 1 pili are encoded by the fim 
operon located in the chromosome of most ETEC strains and are highly conserved. 
While type 1 pili are known to play a critical role in virulence of extraintestinal 
pathogenic E. coli, the present studies represent the first detailed examination of the 
contribution of these pili in ETEC pathogenesis. Here we demonstrate that ETEC type 1 
pili are essential for optimal interactions with intestinal epithelia and that they play a 
critical role in virulence. These data may inform additional approaches toward 
development of broadly protective vaccines for these pathogens of global importance. 
INTRODUCTION 
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Among young children under five years of age in developing countries, diarrhea is a 
leading cause of morbidity and mortality. Enterotoxigenic E. coli (ETEC) is one of the 
most common causes of moderate to severe diarrheal illness and deaths due to 
diarrhea in young children and incidentally is also the leading bacterial cause of 
diarrhea [1]. These bacteria are also a leading cause of hospitalization due to severe 
diarrhea in adults in developing countries [2] and are perennially the predominant cause 
of diarrheal illness among travelers to the endemic regions [3, 4]. Additionally, ETEC 
infections contribute substantially to the burden of diarrheal illness associated with 
sequelae of malnutrition [5, 6], stunted growth [7] and impaired cognitive development 
[8]. The effects of ETEC infections also appear to be more critical in malnourished 
children [5]. Thus these pathogens contribute to a complex pattern of poverty, repeated 
enteric infections, environmental enteropathy [9], and developmental impairment . 
ETEC are defined by the production of heat-labile (LT) and/or heat-stable (ST) 
enterotoxins [10], and virulence requires successful delivery of these toxins to cognate 
receptors on target intestinal epithelial cells. LT binds to cell surface GM1 gangliosides, 
and following cellular entry this toxin activates production of host cAMP; while ST 
peptides bind guanylate cyclase C, stimulating production of cGMP [11]. Resulting 
increases in intracellular concentrations of these cyclic nucleotides modulate ion 
channels on the surface of intestinal cells leading to net losses of sodium chloride and 
water into the intestinal lumen and ensuing acute watery diarrhea [11, 12]. In the 
classical paradigm of ETEC pathogenesis, these bacteria utilize pathovar-specific 
fimbrial or non-fimbrial adhesins, known as colonization factors or CFs [13] which allow 
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them to adhere and colonize the small intestine where toxin delivery occurs. However, 
emerging evidence would suggest that this paradigm is perhaps overly simplistic, and 
that there are several potential adhesins which effectively act in concert to promote 
ETEC engagement of the host [14].  
E. coli encode a multitude of pili assembled by the chaperone/usher pathway, termed 
CUP pili, which are important in virulence. CUP pili are tipped with specialized adhesins 
that recognize specific receptors with stereochemical specificity. CUP adhesins can 
determine both tissue tropism and the course of disease. For example, type 1 pili are 
encoded by the fim operon, and chomosomally encoded as part of the core E. coli 
genome [15, 16]. Type 1 pili are composite fibers comprised of a pilus rod, made up of 
FimA subunits arranged in a right handed helical cylinder [17]. The pilus rod is joined to 
a fibrillum structure tipped with the FimH adhesin that binds mannose with 
stereochemical specificity [16, 18-20].  FimH is critical for virulence in extraintestinal E. 
coli, as it has been well-established that FimH mediated adhesion enables 
uropathogenic E. coli (UPEC) colonization and invasion into bladder epithelial cells [21-
23], as well as the formation of intracellular bacterial communities [24]. ETEC also 
encode pathovar-specific CUP pili (fimbriae) like CFA/I [25] that are encoded on 
virulence plasmids [26]. More than four decades ago, these ETEC-specific colonization 
factors were shown to contribute to development of diarrheal illness in humans [27], and 
consequently they have been the subject of intensive investigation and a major focus of 
ETEC vaccine development. Conversely, although early studies described possible type 
1 pili expression by ETEC [28, 29], relatively little is known about the contribution of 
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these highly conserved structures to virulence. Our more recent observation that the 
expression of the fim operon is enhanced by pathogen-host cell contact [14], prompted 
a thorough investigation of the potential role of type 1 pili in ETEC pathogenesis 
reported here. 
RESULTS 
Type 1 pili promote ETEC binding to intestinal epithelia 
Although a number of earlier studies of ETEC suggested that these pathogens make 
type 1 pili (also previously referred to as type 1 somatic pili or type 1 fimbriae) [29, 30], 
to date there has been no systematic examination of their involvement in ETEC 
virulence. We therefore first performed studies to confirm the production of type 1 pili by 
the prototypical ETEC H10407 strain. Type 1 pili tipped with the FimH adhesin were 
identified on the surface of strain H10407 by transmission electron microscopy after 
immunogold labeling using anti-FimH antibodies (Fig 1a). Similarly, using flow cytometry 
we verified production of type 1 pili in H10407, but not in the corresponding fimH mutant 
strain (Fig 1b). It has previously been shown that FimH is required to initiate the 
assembly of type 1 pili and thus fimH mutants are nonpiliated [31]. The expression of 
type 1 pili is under the transcriptional control of an invertible promoter element that 
governs phase OFF and phase ON populations [32, 33]. Interestingly, mutations that 
inactivate FimH such as the Q133K mutation, bias the fim promoter towards the phase 
OFF state [34]. Thus, compared to the wild type H10407 strain, or pfimH complemented 
mutants, isogenic fimH mutants or those complemented with pQ133K, which encodes 
FimH with a mutation in the mannose binding site [35], were nonpiliated and incapable 
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of yeast agglutination, a phenotypic assay for expression of type 1 pili [36] (Fig 1c) and 
only the wild type and fimH complemented mutants exhibited demonstrable type 1 pili 
expression detected by anti-type 1 pili antibodies in immunoblots (Fig 1d). Next, using 
polarized cultured intestinal epithelia (CIE) derived from the C2BBe1 clone of Caco-2 
cells which produce apical brush borders with defined microvilli similar to human 
intestinal enterocytes [37], we demonstrated that production of FimH was required for 
effective adhesion. Mutants lacking fimH were significantly less adherent than wild type 
ETEC (p<0.0001) (Fig 1e,f), while episomal expression of the fimH gene (pfimH), but 
not the mutant fimH allele (pQ133K), restored adhesion. Additionally, H10407-
fimH:Q133K, which contains the Q133K mutant allele of fimH in the chromosome, 
abrogated yeast agglutination activity and demonstrated significant decrease in 
adhesion to intestinal cells (data not shown). Similarly, mutants lacking the fimA gene 
encoding the major type 1 pili pilin subunit exhibited loss of functional type 1 pili in yeast 
agglutination assays, resulting in significant reduction of adhesion to the CIE (S1 Fig).  
We found that methyl- -D-mannose but not the methyl- -D-galactose control sugar, 
inhibited FimH mediated yeast agglutination by ETEC (Fig 2a) and ETEC adhesion to 
epithelial cells (Fig 2c). Similarly, antibodies generated against the lectin domain of 
FimH (α-FimH), but not control antibodies, separated from pre-immune sera, inhibited 
FimH mediated yeast agglutination with wild type bacteria expressing type 1 pili (Fig 2b) 
and significantly inhibited ETEC adhesion to intestinal cells (Fig 2d). Collectively, these 
data support the idea that ETEC utilize type 1 pili to engage intestinal epithelia.  
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ETEC FimH adhesin binds to intestinal epithelia 
We next examined the ability of the FimH tip adhesin to directly engage the intestinal 
epithelial surface. The purified lectin domain of FimH (FimHLD, 17 kD), representing 
amino acid residues 1-154 of mature FimH, bound to the apical surface of the CIE. In 
contrast, binding of FimHLD:Q133K, which lacks mannose binding activity, was 
markedly diminished (Fig 3a, b) as was binding of the wild type FimHLD protein in the 
presence of exogenous mannose (Fig 3b).  
ETEC are noninvasive luminal pathogens thought to engage the microvilli at the apical 
surface of intestinal epithelial cells. Presumably, the FimH lectin can promote this 
engagement by interacting with mannosylated glycoconjugates on the glycocalyx 
covering the microvilli. Indeed, using transmission electron microscopy, we identified 
FimH by immunogold labeling at the ETEC-microvillus interface (Fig 3c).  
Surface mannosylation enhances FimH-mediated ETEC-epithelial interaction  
Because FimH interacts with mannosylated receptors on the epithelial surface, we 
examined the impact of enhanced glycoprotein mannosylation on ETEC pathogen host 
interactions. Following CIE treatment with kifunensine, an α-mannosidase class 1 
enzyme inhibitor which enhances the display of high-mannose glycoproteins [38], we 
observed a significant increase in FimHLD binding (Fig 4a-b). Likewise, WT ETEC 
adhesion to the kifunensine treated CIE was enhanced relative to the untreated control 
CIE (p<0.0001) (Fig 4c,d). However, kifunensine treatment had no impact on adhesion 
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of the fimH mutant. These data further suggested that availability of mannosylated 
glycoproteins on the host cell surface promotes ETEC adhesion through FimH.  
Type 1 pili act in concert with CFA/I fimbriae for optimal adhesion 
Because ETEC H10407 expresses both type 1 pili and plasmid encoded CFA/I fimbriae 
specific to the ETEC pathovar, we investigated whether these CUP structures acted 
cooperatively in facilitating adhesion to intestinal epithelia. The CFA/I fimbriae are 
encoded by the cfaABCE operon in which cfaE encodes the CfaE tip adhesin [26, 39, 
40]. Interestingly, mutations in either fimH or cfaE significantly reduced adherence of 
ETEC compared to wild type H10407, suggesting that both pili participate in ETEC 
adhesion (S2 Fig). Mutants lacking both the type 1 pili and the CFA/I tip adhesin genes 
(fimH-cfaE) demonstrated further reduction in adhesion compared to either of the single 
mutants (S2 Fig), supporting our hypothesis that structures encoded by these CUP pili 
act in concert.  
Type 1 pili mediate adhesion to human small intestinal enteroids 
While the CIE used in this study possess some features of normal intestinal epithelial 
cells, they are derived from metastatic colon cancer cells which fail to represent the 
diversity of cell types present in intestinal epithelium. Enteroids, derived from human 
intestinal stem cells collected from healthy volunteers [41-43], can recapitulate many 
aspects of normal physiology and preserve features of human intestinal epithelium. 
These include presentation of different cell types including enterocytes, goblet cells, 
Paneth cells, and endocrine cells [44-46]. Therefore, to further assess the contribution 
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of type 1 pili in ETEC adhesion to intestinal epithelia we established polarized intestinal 
epithelial monolayers derived from ileal specimens obtained from normal adult human 
subjects. In these enteroid-derived monolayers we were able to identify enterocytes with 
a defined brush border and distinct microvilli on the apical surface as well as goblet 
cells, and chromogranin A positive cells suggesting that they faithfully reproduce many 
features of surfaces normally presented to bacteria within the intestine (Fig. 5a-e). 
Similar to our studies of CIE, we found that wild type ETEC adhered to the surface of 
stem cell derived polarized small intestinal (ileal) monolayers (Fig 6a,b) in close 
approximation with the microvillus surface (Fig 6c), and that mutation of fimH 
significantly attenuated adherence relative to the wild type parent strain (Fig 6d). Wild 
type bacteria adhered well to polarized monolayers of enteroid collected from multiple 
individuals, while the fimH mutant was persistently deficient in its ability to adhere to all 
target epithelia relative to the parent strain (Fig 6e). These studies suggested that type 
1 pili of ETEC potentially play an important role in specifically directing bacterial 
interaction with the small intestine where release of toxins is thought to provoke the 
efflux of water and salt that lead to diarrhea.   
Type 1 pili promotes optimal toxin delivery to intestinal cells in vitro 
Close contact of ETEC with target epithelial cells is essential for efficient delivery of its 
enterotoxins [47, 48]. To investigate the impact of type 1 pili mediated ETEC-host 
interactions on toxin delivery, we measured the intracellular production of cAMP and 
cGMP, cyclic nucleotide second messenger markers for delivery of LT and ST, 
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respectively, in infected cells. cAMP and cGMP was significantly increased in target 
cells infected with WT H10407 relative to fimH or fimA mutants (Fig. 7a and b). Methyl-
-D-mannose significantly reduced levels of intracellular cGMP and inhibited cAMP 
activation in target cells infected with WT H10407 (Fig 7a and b). These effects were 
observed despite wild type levels of LT being produced by the mutants (Fig 7c). 
Together, these data suggested that type 1 pili are required for optimal delivery of both 
heat-labile and heat-stable enterotoxins to the target epithelial cells.  
Type 1 pili are required for ETEC virulence  
We next examined the contribution of type 1 pili to pathogenesis in the rabbit ileal loop 
model, a classical model of virulence for V. cholerae and ETEC [49]. Both fimH and 
fimA mutants were significantly less adherent than the WT H10407 to rabbit ileal 
intestinal epithelium (Fig 8 a,b). Likewise, while considerable fluid accumulation, a 
hallmark of ETEC virulence, was observed in loops infected with WT H10407 (Fig 8c) 
no demonstrable fluid accumulation was observed in control loops infected with eltAB 
mutants [47] which do not make LT toxin (S1 Table), or those containing only PBS, and 
we detected significantly less fluid accumulation in the loops infected with either the 
fimH or fimA mutants (Fig 8c), suggesting that type 1 pili mediated pathogen-host 
interactions contribute to ETEC virulence in this model.  
Type 1 pili are highly conserved in diverse clinical ETEC isolates 
To investigate the prevalence of functional type 1 pili expression in clinical ETEC 
isolates, we tested 174 geographically and phylogenetically disparate clinical isolates 
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including recently sequenced [50] strains using yeast agglutination assays. Overall, the 
majority (76%) of the clinical isolates demonstrated yeast agglutination activity indicative 
of preserved functional type 1 pili expression among ETEC. Importantly, we observed 
type 1 pili expression in isolates possessing each of the major colonization factors 
(CFs), and in 82% of isolates without any recognizable CFs (Table 1). Overall, these 
data suggest that functional type 1 pili are highly conserved in diverse ETEC clinical 
isolates.  
Collectively data provided here demonstrate the first definitive evidence that type 1 pili 
are essential to the pathogenesis of these highly diverse pathogens. Similar to their 
well-established role in the pathogenesis of uropathogenic E. coli (UPEC) [51] where 
type 1 pili are required for interaction with bladder epithelia, these structures appear to 
be highly conserved in clinical isolates and are critical for ETEC adhesion and effective 
engagement of host intestinal epithelia that are ultimately required for efficient delivery 
of effector molecules including the known toxins. 
DISCUSSION 
Enterotoxigenic E. coli are a remarkably diverse group of pathogens that share plasmid-
encoded effector molecules, namely heat-labile toxin (LT) and/or heat-stable toxins 
(ST). In effect, ETEC pathogenesis can be summarized by the virulence features that 
collectively facilitate the delivery of these toxins [52]. Successful engagement of the 
complex landscape presented by the intestinal mucosae that includes a secreted mucus 
layer as well as the glycocalyx, glycoconjugates on the apical surface of the epithelium 
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[53, 54], represents an essential step in ETEC virulence. Like other enteric pathogens, 
ETEC appear to employ a number of different adhesins (lectins) that recognize specific 
carbohydrate moieties on intestinal epithelia [55-58]. 
While most studies of ETEC adhesion, and consequently vaccine development, had 
previously focused on plasmid-encoded colonization factors, recent studies have 
suggested that bacterial adhesion, intestinal colonization, and toxin delivery ultimately 
represent very complex phenotypes involving the orchestrated deployment of a variety 
of pathovar specific plasmid encoded adhesins [14, 59, 60] as well as highly conserved 
chromosomally-encoded molecules [61] and other virulence factors including mucinases 
[62, 63] . Although a number of early studies had suggested that ETEC have the 
capacity to make type 1 pili [30, 64], their contribution to pathogenesis had not been 
comprehensively investigated. 
Here, we demonstrate convincingly that most ETEC make type 1 pili, that these 
organisms utilize these highly conserved pili to engage the intestinal epithelium, and 
that these interactions are critical for effective delivery of both heat-labile and heat-
stable toxins. Additionally, our data demonstrate that type 1 pili act in concert with the 
plasmid-encoded pathovar specific colonization factors to promote optimal interaction of 
H10407 with host intestinal epithelial surfaces. The precise interactions between type 1 
pili and the host cell surface have not been thoroughly delineated, however, the data 
included here support the involvement of the minor pilin tip adhesin subunit (FimH) in 
mannose-dependent engagement of one or more host cell receptors [65-68]. 
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Before the advent of recombinant techniques to construct isogenic deletion mutants, 
earlier investigations of ETEC H10407-P, a plasmid-cured strain of H10407 which lacks 
the large virulence plasmid encoding CFA/I colonization factor, Knutton et. al. 
suggested that type 1 pili mediated ETEC adhesion to human intestinal biopsies in a 
fashion that was inhibited by exogenous mannose [28, 29]. However, it was suggested 
that these pili were mediating adhesion to the basolateral surface of enterocytes rather 
than the apical side [28]. The data presented here overcome many of the technological 
limitations inherent in these earlier studies and demonstrate convincingly that type 1 pili 
mediate adhesion of ETEC to apical surface of small intestinal enterocytes, where LT 
and ST bind to surface GM-1 and guanylate cyclase C receptors, respectively. 
While ETEC cause a tremendous burden of disease in low-middle income countries, 
and among travelers to these regions, at present, there is no suitable broadly protective 
vaccine to prevent infections caused by ETEC. This in part relates to substantial genetic 
and antigenic heterogeneity within the enterotoxigenic Escherichia coli pathovar. Most 
vaccines to date, in some form, have targeted the plasmid encoded colonization factor 
antigens. The remarkable heterogeneity of these antigens [69] and the fact that many 
ETEC [70, 71], more than half of isolates in some studies [72], do not make a 
recognizable colonization factor have prompted further investigation of these pathogens 
to define additional vaccine target antigens [73].  Our observation that ETEC isolates 
from a phylogenetically and geographically diverse collection of strains express 
functional type 1 pili can potentially inform alternative approaches to design of broadly 
protective immunogens.  
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In summary, the data presented here demonstrate that ETEC utilize type 1 pili for 
optimal engagement of the host intestinal epithelium and that these interactions 
accelerate toxin delivery to the target enterocytes essential for virulence. These studies 
provide an expanded view of ETEC molecular pathogenesis beyond the canonical 
paradigm envisioned more than 40 years ago, and potentially afford new avenues for 
the rational design of strategies to prevent the global burden of disease associated with 
these important pathogens.  
METHODS 
Mutagenesis and cloning 
Isogenic fimH and fimA mutants (S1 Table) were constructed using lambda red 
mediated recombination as previously described [74].To construct fimH mutant, the 
primers jf101413.7 and jf101413.8 (S2 Table) were used to amplify the kanamycin 
resistance cassette from pKD4 plasmid with 60-bp tails corresponding to the DNA 
sequence immediately upstream and downstream of fimH. The resulting amplicon was 
then introduced into H10407 carrying the pKD46 helper plasmid for lambda red-
mediated homologous recombination and mutants were selected on 50 μg/ml 
Kanamycin containing LB-agar plate, and tested for loss of fimH gene by PCR using 
primers jf120913.9 and jf120913.10. A complementation plasmid (pfimH) was 
constructed by amplifying the fimH gene with its native stop codon using primers 
jf120814.1 and jf120814.2 and cloning into pFLAG-CTC plasmid using infusion cloning 
kit (Clontech, Takara Bio, USA). Site-directed mutagenesis of pfimH with primers 
jf031814.1 and jf031814.2 was used to change the CAA codon corresponding to the 
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glutamine residue at position 133 of FimH to AAA codon corresponding to the lysine 
residue resulting in pQ133K (QuikChange, Stratagene, USA). Plasmids pfimH and 
pQ133K (S3 Table) were then introduced into the fimH mutants for complementation. All 
mutants were checked for motility, growth and secretion of known effector molecules 
including LT, EtpA and EatA.  
To construct an expression plasmid for polyhistidine tagged FimH lectin domain 
(FimHLD), we amplified the N-terminal lectin region of fimH gene using primers 
jf042314.1 and jf042314.2. The amplicon was then cloned into pETDUET1 (In-Fusion, 
Clontech). Site directed mutagenesis was used to generate the mannose binding 
deficient FimHLD:Q133K as described above. The resulting plasmids, pfimHLD and 
pfimHLD:Q133K, were then introduced into BL21 (DE3) pLys strain for expression and 
purification of polyhistidine-tagged FimHLD and FimHLD:Q133K. 
Expression and purification of recombinant protein 
Overnight cultures of BL21 (DE3) pLys containing pfimHLD or pfimHLD:Q133K were 
diluted 1:100 into 2 liters of terrific broth supplemented with 100 μg/ml ampicillin and 
grown for 3 h at 37˚C to optical density at 600 nm (OD600) of ~0.7 then induced with 1 
mM IPTG for 3 h at 30˚C. Cells were harvested, lysed and his-tagged proteins were 
purified from the bacterial lysates by nickel affinity chromatography using HisTrap HP 
column (GE healthcare bioscience, PA, USA). His-tagged FimHLD and FimHLD:Q133K 
were further purified by size exclusion column chromatography using HiLoad16/600 
Superdex 200 pg column (GE).     
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Antibody generation and purification  
Anti-FimH polyclonal rabbit antiserum was produced against the lectin domain of FimH 
as previously described [61]. Briefly, two New Zealand White rabbits were immunized 
(Rockland, USA) with recombinant polyhistidine-tagged FimHLD. Antibodies were 
separated from serum components using HiTrap columns prepacked with protein G 
Sepharose (GE). The resulting polyclonal antibodies were then pre-absorbed using 
lyophilized strain AAEC191-A [15], and affinity purification of antibody against FimHLD 
immobilized on nitrocellulose was performed as previously described [61, 75]. 
Bacteria and Cell culture 
All experiments were carried out using prototypical ETEC strain H10407 or the isogenic 
mutants (S2 Table). Bactria were grown at type 1 pili inducing conditions by following 
static incubation for 24 h at 37˚C followed by subculturing at 1:100 for additional 24 h 
statically at 37˚C [34] in LB media supplemented with or without antibiotic, as 
appropriate, unless otherwise stated. C2BBe1 cells (ATCC Accession Number CRL-
2102), a subclone of the Caco-2 cell colonic adenocarcinoma line, was used for 
generation of the cultured intestinal epithelium (CIE). In order to generate polarized 
monolayers which form an apical brush border, with microvilli morphologically 
comparable to that of the human intestinal epithelium [37], we seeded ~2 x105 C2BBe1 
cells onto Transwell filters (0.4µM polystyrene membrane, 6.5mm diameter insert) in 
DMEM media supplemented with 10% FBS and 10 µg/ml human transferrin (Lonza, 
MD, USA) and grew at 37˚C with 5% CO2 for three weeks for CIE (polarized monolayer 
culture). Media were changed every 2-3 days. Formation of microvilli was verified by 
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transmission electron microscopy. Caco-2 cells (ATCC) were cultured in MEM media 
supplemented with 20% FBS. T-84 (ATCC) cells were cultured in DMEM/F12 (1:1) 
media supplemented with 5% FBS. 
Flow cytometry 
Strains grown under type 1 pili inducing conditions were processed for flow cytometric 
analysis. For surface staining, bacterial pellets were washed once with PBS, fixed in 2% 
paraformaldehyde for 15 min and then incubated with 1%BSA in PBS for 30 min at RT. 
Bacteria were then incubated with primary antibody (α-FimH) at RT for 45 min. After 
washing with PBS, secondary antibody staining was performed at RT in the dark with 
species-specific antibodies conjugated with AlexaFluor 546 for an additional 45 min. 
Bacteria were then washed with PBS and resuspended in 100 μl of PBS for acquisition 
by flow cytometry (FACSCalibur, BD Biosciences). A minimum of 50,000 organism 
counts were acquired (CellQuest software, Becton Dickinson), and subjected to 
subsequent analysis (FlowJo, v7.6.3). 
Type 1 pili extract preparation and detection: 
Type 1 pili were extracted by following a previously described method with some 
modifications [76]. Briefly, bacteria grown in type 1 pili inducing conditions were 
harvested, re-suspended in 1 ml of 1 mM Tris-HCl (pH 8.0) and incubated at 65°C for 1 
h with occasional vortexing and pelleted by centrifugation (15,000 × g for 5 min). The 
supernatant was then transferred to another tube, and an aliquot was precipitated in salt 
(300 mM NaCl and 100 mM MgCl2) by incubating overnight at 4°C, followed by 
46 
 
centrifugation at 20,000 × g for 10 min at 4°C. The protein pellet was re-suspended in 1 
mM Tris-HCl. Fimbrial extracts were separated by sodium dodecyl sulfate (SDS)-15% 
polyacrylamide gel electrophoresis minigels (Bio-Rad). Proteins were either stained with 
Coomassie brilliant blue or transferred to nitrocellulose membranes (Bio-Rad) using a 
Mini Trans-Blot electrophoretic cell (Bio-Rad) for 60 min at 100 V. The membrane was 
blocked with 5% milk-PBS supplemented with 0.05% Tween 20 (Pierce). Incubations 
with primary (1:5,000) and secondary (1:5,000) antibodies were carried out for 1 h at 
RT. Chemiluminescent substrate (Clarity Western ECL substrate, Bio-Rad) was used 
for detection. 
Yeast agglutination assay 
Yeast agglutination as a phenotypic test for the production of type 1 pili [36], was 
performed using the following conditions: strains to be tested were grown in 1 ml Luria 
broth at type 1 pili inducing conditions, harvested and adjusted to OD600 of 1.0 in PBS. 
Agglutination was performed on glass slides by mixing 20 μl bacteria with an equal 
volume of bakers’ yeast suspension adjusted to OD600 of 1 in PBS. 
Adhesion assays 
For adhesion assays, bacteria to be tested were grown at type 1 pili inducing conditions 
and diluted at 1:10 in pre-warmed cell culture media prior to infection. Serial dilutions of 
each inoculum were plated on Luria agar for CFU count. Infected CIE were incubated at 
37°C and 5% CO2 for 1 h, washed with pre-warmed tissue culture medium 3 times with 
gentle shaking (100 rpm) for 1 min each. The CIE were then either lysed in 0.1% Triton 
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X-100 for 5 min, and the cell associated bacteria were recovered by plating lysates onto 
Luria agar, or processed for fluorescence microscopy for enumeration of bacteria 
attached to the cells. 
Fluorescence microscopy 
To investigate the binding of FimH in the context of intestinal epithelial cells, 100 µl of 
50 µg/ml biotinylated FimHLD or FimHLD:Q133K was incubated with CIE. After an hour 
of incubation at 37˚C unbound FimHLD were washed off with tissue culture media, the 
cells were fixed with 2% paraformaldehyde for 30 min at room temperature (RT), 
washed twice with PBS, and blocked with 1% BSA-PBS for another 30 min at RT. 
Streptavidin coated Qdot 594 was then used at 1:100 dilution in 1% BSA-PBS to detect 
biotinylated FimHLD bound to the cell surface. For detection of ETEC adhesion, 
infected CIEs were incubated with anti-O78 antibody followed by fluorescent labeled 
secondary. Cell membranes and nuclei were stained as previously described (CellMask, 
red for membrane and DAPI for nuclei; Invitrogen) [61]. Images were acquired on a 
Zeiss LSM510 confocal microscope, and files were converted to TIFF image using 
ImageJ (v1.45). Signals were quantified using Volocity software (version 6.2; 
PerkinElmer, Inc.).  
Transmission immunoelectron microscopy  
For localization of FimH on intestinal epithelium, ETEC infected CIE were fixed in 
2% paraformaldehyde/0.02% glutaraldehyde (Polysciences Inc., Warrington, PA) in 100 
mM PIPES/0.5 mM MgCl2, pH 7.2 for 1 h at 4°C.  Samples were washed with PIPES 
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buffer, blocked with 5% FBS/5% NGS for 20 min and subsequently incubated with 
rabbit anti-FimH antibody for 1 h, followed by secondary goat anti-rabbit antibody 
conjugated to 18 nm colloidal gold for 1 h. Samples were washed in buffer and postfixed 
in 1% osmium tetroxide (Polysciences Inc.) for 1 h.  Samples were then rinsed 
extensively in dH2O prior to en bloc staining with 1% aqueous uranyl acetate (Ted Pella 
Inc., Redding, CA) for 1 h.  Following several rinses in dH2O, samples were dehydrated 
in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella 
Inc.).  Sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica 
Microsystems Inc., Bannockburn, IL), stained with uranyl acetate and lead citrate, and 
viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc., 
Peabody, MA) equipped with an AMT 8 megapixel digital camera (Advanced 
Microscopy Techniques, Woburn, MA). 
Growth and differentiation of human small intestinal epithelial cells 
Enteroids were grown as previously described in detail [45] from purified intestinal cell 
lines, maintained at the Washington University Digestive Diseases Research Core 
Center BioSpecimens Core under a protocol approved by the Institutional Review 
Board. Briefly, cells were thawed and re-suspended in Matrigel (BD Biosciences, San 
Jose, CA, 15 L/well in 24 well plates), and incubated at 37°C with a 1:1 mixture of L-
WRN conditioned media (CM) and primary culture media (Advanced DEM/F12, 
Invitrogen) supplemented with 20% fetal bovine serum (FBS), 2 mM L-glutamine, 100 
units/mL penicillin, 0.1 mg/mL streptomycin, 10 M Y-27632 (ROCK inhibitor; Tocris 
Bioscience, R and D Systems, Minneapolis, MN), and 10 M SB 431542 (transforming 
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growth factor-ß type 1 receptor inhibitor; Tocris Bioscience, R and D Systems). For 
polarization, cells were added to Transwell filters (Corning) and incubated in 
differentiation media (1:20 mixture of L-WRN CM and primary culture media) lacking SB 
431542. Cells were grown to confluence for 3 days in differentiation media before use.  
Histological analyses of eneteroid-derived human intestinal epithelial monolayers 
For histological analysis (Day 3), enteroids grown on transwell were fixed in 3.7% 
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) for 15 min, washed 
once with PBS and processed for paraffin embedding. Transverse sections (5 μm) were 
stained with hematoxylin and eosin (visualized with a Zeiss Axioskop 2 MOT 
microscope fitted with a CRI Nuance FX multispectral imaging system, Cambridge 
Research and Instrumentation), or used for immunostaining. For immunostaining, 
sections were de-paraffinized and hydrated, boiled in Unmasking Solution (Vector 
Laboratories, Burlingame, CA) for 25 min, rinsed in PBS, blocked in 1% bovine serum 
albumin/0.1% Triton-X100 for 30 min and incubated with primary antibody at 4°C 
overnight. Primary antibodies included rabbit anti- ChgA (1:100, Abcam, Cambridge, 
MA), rabbit anti-Muc2 (1:100, Santa Cruz Biotechnology, Inc., Dallas, Texas), mouse 
monoclonal anti-Villin 1 (1:100; Santa Cruz Biotechnology, Inc.). Slides were rinsed 3 
times with PBS and incubated for 60 min at RT with species specific secondary 
antibodies (1:200; Invitrogen) conjugated to AlexaFluor488 or AlexaFluor546. For 
detection of bacteria, enteroids (grown for 3 days) were infected for 1 h, washed 3 times 
with pre-warmed media, fixed in 3.7% paraformaldehyde and either processed for 
fluorescent microscopy or embedded in paraffin. For the detection of tight junction 
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formation, antibody against zonula occludens-1 (anti-ZO-1, mouse monoclonal, 
Invitrogen) was used at 1:100 dilutions followed by anti-mouse secondary antibodies 
conjugated to AlexaFluor488 (1:200, Invitrogen). Paraffin embedded sections were 
deparaffinized and processed for immunostaining with anti-O78 antibody (1:200) 
followed by secondary antibodies (1:200; Invitrogen) conjugated to AlexaFluor 546 for 
the detection of cell associated bacteria. UEA-1 lectin conjugated to FITC (1:100, 
Sigma) was applied during secondary antibody incubation. Slides were washed 3 times 
in PBS and stained with DAPI (Molecular Probe) to visualize nuclei and cellmask red 
(1:2000, Invitrogen) to visualize plasma membrane and mounted with ProlongGold 
antifade reagent (Molecular Probes) for confocal microscopy (Nikon ECLIPSE Ti 
confocal microscope equipped with NIS-Elements imaging software). To examine ETEC 
association with microvilli of polarized primary human small intestinal epithelial cells, 
infected monolayers were processed for transmission electron microscopy following 
protocol mentioned above.    
Toxin secretion assay 
LT toxin secretion by different strains was measured using previously established GM1-
ELISA method [77]. Briefly, ELISA plates (Costar, Corning, NY) were coated with 100 
μl/well of 1 μg/ml monosialoganglioside GM1 (Sigma, G-7641), and incubated overnight 
at RT. After blocking with 2% BSA in PBS-Tween, 100 μl of clarified culture supernatant 
from overnight Luria broth cultures of bacteria was added to wells in triplicate and 
incubated for 1 h at 37˚C. The wells were then washed and incubated with 100 μl of a 
1:5000 dilution of rabbit anti-LTB polyclonal antisera for 1 h. Plates were again washed 
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and then incubated with 100 μl of a 1:5000 dilution of anti-rabbit secondary conjugated 
with HRP for another hour. Finally plates were developed with 100 µL per well of TMB-
H2O2 (KPL) substrates and read immediately at 630nm for kinetic measurement (Eon, 
BioTek instruments, VT, USA). 
Cyclic nucleotide assays 
Caco-2 cell monolayers grown in 96-well plates were infected with WT or mutant strains 
and used to determine alterations in cAMP. After 2 h of infection wells were washed 
with pre-warmed tissue culture media, incubated for an additional 2.5 h, cells lysed in 
sample buffer and intracellular cAMP concentrations were then determined by ELISA 
(cAMP Direct EIA, Arbor Assays, MI, USA). Similarly, T-84 cell monolayers grown in 96-
well plates were used to determine cGMP concentrations following infection. 1.5 h after 
infection, wells were washed 3 times with pre-warmed tissue culture media, incubated 
for an additional 3 h, lysed sample buffer, and intracellular cGMP determined (cGMP 
Direct EIA, Arbor Assays, MI, USA). 
Rabbit ileal loop assays 
The rabbit ileal loop (RIL) assay was performed as previously described [49, 78]. Briefly, 
bacteria were grown overnight in Luria broth at 37°C, at type 1 pili indicung conditions, 
then washed with PBS, and diluted yield to a target inoculum of ~1X106 CFU/ml/loop. 
Adult albino rabbits (New Zealand strain) weighing 1.5–2.0 kg were fasted for 24 h and 
allowed only water. Following induction of anesthesia with intravenous sodium 
pentobarbital (0.5 mL/kg body mass), the abdominal cavity was entered, the intestine 
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exposed and the ileum localized. Here, loops of 5 cm in length were created with 
surgical ligatures, with 2 cm intervals between each loop to yield 5-6 loops per rabbit. 
Loops were then inoculated with either wild type H10407 as a positive control or mutant 
strains. Animals were euthanized ~18 h post infection with sodium pentobarbital, the 
intestine exposed and the ileocaecal region was then removed. The volume of fluid 
accumulation determined per unit length of gut within each segment, after which tissue 
specimens from the corresponding segment were collected, fixed in formalin (10%), 
paraffin-embedded and subsequently processed for examination of villous associated 
bacteria following protocol mentioned above.  
Ethics statement  
Rabbit ileal loop protocol conducted at icddr,b was reviewed and approved by the 
institution’s Animal Experimentation Ethics Committee (AEEC). Experimental 
procedures were carried out by veterinarians at the animal facility in accordance with 
relevant guidelines. The rules and guidelines followed at icddr,b for animal care and 
use adhere to the recommendations, with some modifications, stated in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health (NIH). 
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CHAPTER TWO: FIGURES 
 
Figure 1. Type 1 pili expression promotes optimal adhesion of ETEC to intestinal 
epithelia. a. Transmission electron micrograph of ETEC H10407 expressing type 1 pili. 
The FimH tip adhesin was detected using α-FimH antibody and gold secondary 
antibody conjugate. b. Flow cytometric analysis of type 1 pili expression by ETEC 
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H10407 and fimH mutants. c. Assessment of type 1 pili function using yeast 
agglutination assays. Negative yeast agglutination reflected the loss of type 1 pili 
activity. d. FimA immunoblot of type 1 pili extracts from static culture of WT ETEC, fimH 
mutants and mutants complemented with wild type fimH gene (pfimH) or mutant fimH 
gene (pQ133K). e. Confocal microscopic images showing adhesion of WT ETEC, fimH 
mutants or complemented mutants to polarized cultured intestinal epithelia. Bacteria 
(anti-O78, green), cell membrane (CellMask, red), nuclei (DAPI, blue). f. Quantitative 
analysis was done by counting number of bacteria per focus area. Horizontal dashed 
lines represent geometric means of 3 combined individual experiments. P values were 
calculated by nonparametric Mann-Whitney test. *** indicates p<0.0001. 
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Figure 2. Inhibition of type 1 pili mediated interaction impairs ETEC adhesion. 
Yeast agglutination assay of WT ETEC (a) is inhibited by methyl-α-D-mannose but not 
equimolar concentrations of methyl-α-D-galactose control sugar. b. Anti-FimH 
antibodies, generated against the lectin domain of FimH, but not preimmune sera inhibit 
yeast agglutination. c. In vitro adhesion of WT ETEC or fimH mutants in the absence or 
presence of methyl-α-D-galactose or methyl-α-D-mannose. d. WT ETEC adhesion is 
inhibited by anti-FimH antibodies. The percentage of cell associated bacteria represents 
the proportion of bacteria associated with the CIE at the end of 1 h relative to the 
inoculum. Bars represent mean vaules + SEM (n=5). P values were calculated by 
nonparametric Mann-Whitney test. * indicates p<0.05. 
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Figure 3. FimH adhesin of ETEC interacts with intestinal epithelial cells. a. 
Confocal microscopy images show binding of the biotinylated FimH lectin domain 
(FimHLD) or FimHLD:Q133K to the apical surface of cultured intestinal epithelium (CIE). 
Biotinylated FimHLD was detected with streptavidin-conjugated fluorescent 
nanocrystals (Qdot, green); plasma membranes were stained with CellMask (red) and 
nuclei with DAPI (blue).  Image at right shows three dimensional reconstruction of z 
stacks of CIE following interaction with FimHLD or the mutant protein. b. Quantitative 
analysis of FimHLD binding to CIE represented in panels a using Volocity three-
dimensional (3D) image analysis software (version 6.2; PerkinElmer, Inc.). P value was 
calculated using nonparametric Mann-Whitney testing. c. Immunoelectron microscopy 
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images of CIE infected with ETEC H10407. Left panel, microvilli structure at the apical 
surface of the CIE; right panels show immunogold labeling of FimH localized to the 
ETEC-host interacting surface. 
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Figure 4. Enhanced presentation of mannosylated glycoproteins increases FimH 
binding and ETEC adhesion. a. Confocal microscopy images detecting FimHLD 
binding to the kifunensine treated CIE. Biotinylated FimHLD was detected with 
streptavidin-conjugated fluorescent nanocrystals (Qdot, green) and nuclei with DAPI 
(blue). b. Quantitative analysis of FimHLD binding to CIE represented in panels a using 
Volocity three-dimensional (3D) image analysis software (version 6.2; PerkinElmer, 
Inc.). c. Confocal microscopic images showing ETEC adhesion to kifunensine treated 
72 
 
CIE. The CIE grown on trans-well filters were treated with kifunensine and infected with 
WT ETEC or fimH mutants. One hour post infection wells were processed for 
microscopic examination. Bacteria (green), cell membrane (red), DAPI (blue). d. 
Quantitative analysis was done by counting number of bacteria present per focus area. 
Horizontal dashed line represent mean of 2 individual experiments. P values were 
calculated by nonparametric Mann-Whitney test. *** indicates p<0.0001. 
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Figure 5. Properties of small intestinal enteroid cultures. a. Hematoxylin and eosin 
staining, DIC, and UEA1 lectin immunofluorescence confocal microscopic images 
showing formation of continuous monolayers. The apical surface is detected in the 
bottom image with FITC conjugated UEA1 lectin. b.  UEA1 and anti-villin 1 antibody 
immunofluorescence in Laser Scanning Confocal Microscopy (LSCM) images from 
sections of polarized small intestinal enteroid monolayers. Nuclei (DAPI) are shown in 
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blue. c. LSCM of sections showing MUC2 immunofluorescence (red) in probable goblet 
cell and co-localization with UEA1 in the merged image. d. Chromogranin A positive 
cells (red). e. Transmission electron microscopy (3000x) of polarized small intestinal 
enteroid monolayer sections showing a goblet cell flanked by enterocytes with distinct 
microvilli on the apical surface.  Transwell filters in sections are indicated by *. 
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Figure 6. Type 1 pili are required for optimum adhesion to human small intestinal 
enteriods. a. Representative laser scanning confocal microscopy (LSCM) images of 
sections prepared from polarized enteroid small intestinal monolayers infected with WT 
H10407 (red, anti-O78). Surface staining with the UEA1 lectin is shown in green. Nuclei 
are stained in blue (DAPI). b. Three dimensional reconstruction of LSCM z stacks of 
ETEC H10407 infected polarized monolayer of enteroids showing the distribution of 
zonula occludens-1 (ZO-1, green) at the apical surface. Bacteria were visualized with 
anti-O78 (red) and nuclei are stained with DAPI (blue). c. Transmission electron 
microscopy images of ETEC H10407 adhering to microvilli on the surface of small 
intestinal enteroids (magnification 7500x and 15000x for left and right images 
respectively). d. LCSM images of wild type (wt) versus fimH mutant bacteria adherent to 
the surface of small intestinal enteroids Bacteria were visualized with anti-O78 (green) 
and cell membranes with CellMask (red), nuclei (DAPI, blue). e. Quantitative analysis of 
ETEC adhesion to enteroids represented in panel d. Each dot plot represents adhesion 
data obtained using ileal enteroids derived from two individual subjects. Horizontal lines 
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represent geometric means of data combined from 2 independent experiments. P 
values were calculated by nonparametric Mann-Whitney testing.  
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Figure 7. Type 1 pili mediated interactions enhance toxin delivery.  
a. Quantification of intracellular cGMP in infected cells. Cells were infected with WT 
ETEC in the absence or presence mannose sugar or with fimH or fimA mutants. Cells 
infected with STp/STh, ST mutants, represent basal level of cGMP in cells. b. 
Quantification of the amount of intracellular cAMP in infected cells. Cells were infected 
with WT ETEC in the absence or presence mannose sugar or with fimH or fimA 
mutants. Cells infected with eltAB, LT mutants, represent basal level of cAMP in cells. c. 
LT secretion by different mutants. Each bar represent mean with SEM (error bar) of 2 
experiments consisting of 5 replicates per experiment for each strain. All P values were 
calculated by nonparametric Mann-Whitney test. *** p<0.0001. 
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Figure 8. Type 1 pili are required for virulence in the rabbit ileal loop assay.  
Type 1 pili are required for optimal bacterial engagement of rabbit intestinal epithelia.  a. 
sections of rabbit ileum stained with anti-O78 (bacteria top, green) or anti-FimH 
(bottom). Nuclei are stained with DAPI (blue) and membranes are stained with CellMask 
(red). b. bacteria adherent to the ileal mucosal surface following infection with wild type 
ETEC H10407 or fimH and fimA mutants. c. Type 1 pili are required for toxicity in the 
rabbit ileal loop assay. Shown in the graph is the amount of fluid accumulation in each 
loop infected with WT or fimH or fimA mutants 18 h post inoculation. Loops infected with 
eltAB mutants or mock infected (PBS) were used as controls. Date represent summary 
of experiments from different rabbits (n=7). Inset shows image of infected ileal loop of 
one representative experiment.  
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CHAPTER TWO: TABLE 
Table 1: Relationship of functional type 1 pili expresion to colonization factors  
CF designation(s) CF expression 
Type 1 pili 
expression 
 number  % number % 
CFA/I, CS21 28  16 26 93 
CS1, CS3, CS21 15  8.6 2  13 
CS7 14  8 14  100 
CS2, CS3, CS21 11  6.3 10 91 
CS5, CS6 9  5.2 9  100 
CFA/I 7  4 7  100 
CS1, CS3 6  3.4 2  33 
CS21 6  3.4 2  33 
CS17 5  2.9 5  100 
CS20, CS21 5  2.9 5  100 
CS4, CS6 5  2.9 1  20 
CS2, CS3 4  2.3 2  50 
CS14 3 1.7 2 67 
CS6, CS21 3 1.7 3 100 
CS1 2 1.1 2 100 
CS1, CS3, CS20, 2 1.1 0 0 
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CS21 
CS6 2 1.1 2 100 
CS6, CS20, CS21 2 1.1 2 100 
CS6, CS8 2 1.1 2 100 
CFA/I, CS20, CS21 1 0.6 1 100 
CS1, CS21 1 0.6 0 0 
CS12, CS20 1 0.6 1 100 
CS12, CS20, CS21 1 0.6 1 100 
CS19 1 0.6 1 100 
CS2, CS3, CS20 1 0.6 1 100 
CS2, CS3, CS20, 
CS21 1 
0.6 0 0 
CS5 1 0.6 1 100 
CS5, CS6, CS21 1 0.6 1 100 
Undetected 34  19.5 28  82 
total + isolates 140* 80 133* 76 
*of n=174 total isolates queried 
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CHAPTER TWO: SUPPLEMENTARY DATA 
 
S1 Fig. Type 1 pili mediated ETEC adhesion to epithelial cells. 
a. Adhesion by wild type (wt) bacteria or the fimH::Q133K mutant. The percentage of 
cell associated bacteria represents the proportion of bacteria associated with the 
epithelial cells 1 h post infection relative to the inoculum. b. Adhesion assays 
of wt, fimA mutant and fimA mutant complemented in trans with pFimH, or the vector 
control plasmid. Yeast agglutination phenotypes for the wt and mutant bacteria are 
shown below each column of data in the graphs. For data in parts a and b bars 
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represent the mean. Error bar, SEM (n = 5). P values were calculated by nonparametric 
Mann-Whitney test. ** represents p<0.01; *p<0.05. 
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S2 Fig. Type 1 pili act in concert with CFA/I fimbriae for optimal adhesion. 
In vitro adhesion assay to Caco-2 cells infected with either WT H10407 or different 
mutants, including fimH and cfaE single mutants or fimH-cfaE double mutants. The 
percentage of cell associated bacteria represents the proportion of bacteria associated 
with Caco-2 cells at the end of 1 h relative to the inoculum. Different color dots 
represent data from different experiments, horizontal dashed lines represent geometric 
mean values. P values were calculated by nonparametric Mann-Whitney test. *** 
indicates p<0.0001. 
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S1 Table. Strains used in this study 
strain 
designation 
Genotype Description Reference 
H10407 wild type ETEC serotype 078:H11, LT+LST+ [74] 
jf2944 fimH::kan 
fimH; fimH gene is replaced with 
kanamycin resistant gene  
This study 
jf4622 
fimH::kan 
(pfimH) 
pfimH; complemented fimH mutants 
containing wild type fimH gene in 
pFLAG-CTC plasmid, kanamycin and 
ampicillin resistant 
This study 
jf4624 
fimH::kan 
(pfimH:Q133K) 
pQ133K; complemented fimH mutants 
containing mutant allel of fimH gene 
(fimH:Q133K) in pFLAG-CTC plasmid, 
kanamycin and ampicillin resistant 
This study 
jf2003 fimA::kan 
fimA; fimA gene is replaced with 
kanamycin resistant 
This study 
jf2051 
fimA::kan 
(pfimA) 
pfimA; complemented fimA mutants 
containing fimA gene at the multiple 
cloning site of ptrc99A plasmid, 
This study 
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kanamycin and ampicillin resistant 
jf2379 
fimA::kan 
(ptrc99A) 
fimA (control); vector control, 
complemented fimA mutants without 
the fimA gene at the multiple cloning 
site of ptrc99A plasmid, kanamycin 
and ampicillin resistant 
This study 
jf1862 cfaE::kan 
cfaE; cfaE gene is replaced with 
kanamycin resistant gene 
[75] 
jf2945 
fimH::kan, 
cfaE::cm 
fimH-cfaE double mutants; fimH gene 
is replaced with chloramphenicol 
resistant gene and cfaE gene is 
replaced with kanamycin resistant 
gene 
This study 
jf4615 
BL21DE3 pLys 
(pfimHLD-his) 
BL21DE3 pLys (pETDUET1-fimHLD-
his); the lectin domain encoding part 
of fimH gene inserted at multiple 
cloning site 1 of pETDUET1 
expression vector, Ampicillin resistant 
This study 
jf4617 
BL21DE3 pLys 
(pfimHLD:Q133
BL21DE3 pLys (pETDUET1-
fimHLD:Q133K-his); mutant allele of 
This study 
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K-his) the lectin domain encoding part of 
fimH, fimH:Q133K gene inserted in-
frame at multiple cloning site 1 of 
pETDUET1 expression vector, 
Ampicillin resistant 
jf4638 fimH:Q133K 
H10407-Q133K; H10407 strain with a 
point mutation introduced in the 
mannose binding pocket of fimH on 
the chromosome 
This study 
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S2 Table. Primers used in this study 
Primers Sequence Description 
jf101413.7 CCATTCAGGCAGTGATTAGCAT
CACCTATACCTACAGCTGAACC
CGAAGAGATGATTGTAGTGTA
GGCTGGAGCTGCTTC 
Forward, fimH deletion primer; 60 
nucleotides homology tail 
immediately upstream from fimH.p1 
region of pKD4 
jf101413.8 AAGGGCTAACGTGCAGGTTTT
GTAGGTCTGATAGCGTAGCGC
CTCAGGTACCAGCATTAGCATA
TGAATATCCTCCTTA 
Reverse, fimH  deletion primer; 60 
nucleotides homology tail 
immediately downstream from 
fimH.p2 region of pKD4 
jf101413.9 TGGCAACACATTGAATACTGG Forward, fimH mutant test primer 
jf101413.10 TGCCAGATGCGACGCTGACGC Reverse, fimH mutant test primer  
jf062116.1 GAATTTGTAAAGAACCCACGTG
TGCAGGATTTGCTGGCAAAGA
ATGATAAAGGATAAACGGTTTA
AACGATATCGGATCCA 
Forward, cfaE deletion primer; 60 
nucleotides homology tail 
immediately upstream from cfaE. 
nucleotide sequence of cat gene 
jf062116.2 TTAACAAACAGATTACCTATTTA
CAATATTGGCGCGCAATAGCG
CCAATATTGTTGTTATACTAGT
ATTACCCTGTTATCC 
Reverse, cfaE deletion primer; 60 
nucleotides homology tail 
immediately downstream from cfaE. 
nucleotide sequence of cat gene 
jf042314.1 AGGAGATATACCATGATGAAAC
GAGTTATTACCCTGT 
Forward infusion primer; 
nucleotides upstream of NcoI 
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cloning site of pETDUET1 
plasmid.22 nucleotides of fimH from 
the start codon site 
jf042314.2 ATGCGGCCGCAAGCTTTAGTG
GTGATGATGGTGATGGCCGCC
AGTGGGCACCAC 
Reverse infusion primer; 
nucleotides downstream of hindIII 
cloning site of pETDUET1 plasmid. 
nucleotides for 6xhistidine tag 
with stop codon. last 18 
nucleotides of fimH without stop 
codon 
jf120814.1 ATATCATATGAAGCTATGAAAC
GAGTTATTACCCTGT 
Forward infusion primer; 
nucleotides upstream of HindIII 
cloning site of pFLAG-CTC 
plasmid.22 nucleotides of fimH from 
the start codon site  
jf120814.2 TGTAGTCGACAGATCTTATTGA
TAAACAAAAGTCACG 
Reverse, infusion primer; 
nucleotides downstream of hindIII 
cloning site of pFLAG-CTC plasmid. 
last 22 nucleotides of fimH with stop 
codon 
jf031814.1 CTCATTAATTGCCGTGCTTATT
TTGCGAAAGACCAACAACTATA 
Forward, mutagenesis primer for 
Q133K allele; point mutation is 
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underlined 
jf031814.2 TATAGTTGTTGGTCTTTCGCAA
AATAAGCACGGCAATTAATGAG 
Reverse, mutagenesis primer for 
Q133K allele; point mutation is 
underlined 
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S3 Table. Plasmids used in this study 
 
Plasmid Description Reference 
pFLAG-CTC-fimH Complementation plasmid; fimH gene cloned 
into pFLAG-CTC plasmid, Ampr 
This study 
pFLAG-CTC-
fimH:Q133K 
Complementation plasmid; fimH:Q133K 
mutant allele cloned into pFLAG-CTC plasmid, 
Ampr 
This study 
pETDUET1-fimHLD-
his 
Expression plasmid for purification of FimH 
lectin domain (FimHLD),Ampr  
This study 
pETDUET1-
fimHLD:Q133K-his 
Expression plasmid for purification of mutated 
FimH lectin domain (FimHLD:Q133K), Ampr 
This study 
pFLAG-CTC Used as a backbone for complemented 
plasmid, Ampr 
Sigma 
pETDUET-1 Used as a backbone for expression plasmid, 
Ampr 
Novagen 
pKD46 Helper plasmid for λ-Red mediated 
recombination, Ampr 
[66] 
pKD4 Template plasmid for kanamycin resistant 
gene amplification, Kmr 
[66] 
Ampr- ampicillin resistance, Kmr- kanamycin resistance. 
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CHAPTER THREE 
LT induced modification of host glycoproteins alter FimH mediated ETEC-host 
interactions 
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ABSTRACT 
There is no broadly protective vaccine available against enterotoxigenic E. coli (ETEC), 
the major bacterial cause of acute diarrheal illness in children and travelers. Delivery of 
ETEC toxins to the target epithelial cells requires direct pathogen-host interaction. 
Recent studies suggest that ETEC employ multiple factors to directly engage host cells, 
potentially offering additional targets to interdict toxin delivery. Interestingly, earlier 
studies reported that heat labile toxin (LT) enhances ETEC-host interactions. Although 
the mechanism of toxin-induced fluid secretion is fully delineated, how the toxin 
enhances ETEC-host interactions is undefined. Here, we demonstrate that LT 
manipulates host pathways in a way that enhances glycoprotein synthesis and shifts 
glycan synthesis towards production of mannosylated glycans. Additionally, LT 
increases expression of CEACAM6, a mannosylated glycoprotein receptor of the FimH 
adhesin, on intestinal epithelial cells, to facilitate ETEC adhesion. Moreover, we found 
that FimH mediated interactions influence mouse intestinal colonization, particularly in 
the presence of microbiota. However, the loss of FimH activity increases expression of 
other bacterial adhesion molecules in mice during transit through the mouse intestinal 
tract, reinforcing the importance of functionally complementary adhesins. Collectively, 
data presented here offer a mechanistic explanation of LT-induced enhancement of 
ETEC engagement with host intestinal epithelia, and identify a novel ETEC-host 
interaction. These findings expand our understanding of ETEC pathogenesis and may 
inform a rational approach to ETEC vaccine design.     
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INTRODUCTION 
Enterotoxigenic E. coli (ETEC) are among the most frequently isolated bacterial 
pathogens from cases of moderate to severe diarrheal illness and deaths due to 
diarrhea in young children in the developing countries (1). ETEC infections are 
associated with malnutrition (2, 3), poor physical growth (4) and impaired cognitive 
development (5), and also appear to be more prevalent in malnourished children (2). 
ETEC are also the major pathogens associated with diarrheal illness among travelers to 
the countries lacking improved sanitation and safe drinking water (6, 7). Unfortunately, 
there is no broadly protective vaccine against these pathogens. 
Production of heat-labile (LT) and/or heat-stable (ST) enterotoxins are the principal 
features that define ETEC (8), and pathogenesis requires successful delivery of these 
toxins to the target epithelial cells (9).  LT holotoxin is comprised of pentameric LTB 
subunit and the active LTA subunit (10). Following delivery, LT binds to GM1 receptors 
on the cell, is internalized. The LTA subunit constitutively activates adenylate cyclase 
via ADP-ribosylation of the α-subunit of the host Gs protein (11), which ultimately 
increases intracellular cyclic-AMP (cAMP) and activates cAMP-dependent protein 
kinase (PKA). Activated PKA mediated phosphorylation then stimulates several ion 
transporters, resulting in excessive secretion of fluid and electrolytes into the intestinal 
lumen (12). Likewise, ST binds to guanylyl cyclase receptors on the cell and increases 
intracellular cGMP, which stimulates different ion channels (9, 13, 14). In the classical 
model of ETEC pathogenesis, these bacteria utilize pathovar-specific fimbrial or non-
fimbrial adhesins, known as colonization factors or CFs (15, 16) to adhere and colonize 
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the small intestine for toxin delivery. However, emerging evidence suggests that ETEC 
engagement of the host is complex and may require collection of adhesins for efficient 
interaction (17-21). 
Bacterial pathogens possess an array of secreted or cell bound adhesive factors which 
allow them to stick with specific host cells for initial engagement (22-24). Among the 
most studied bacterial adhesive factors are the heteromeric surface appendages known 
as pili or fimbriae (24, 25). These pilus structures present the adhesin subunit at the tip 
to recognize different receptors of the host cell surfaces for adhesion. Many of these 
receptors are glycoconjugates, including glycolipids and glycoproteins (26, 27), 
decorated with different sugar residues (glycans), and are ubiquitous on epithelial cell 
surfaces. Glycoproteins, including mucins, are major constituents of the physical 
intestinal barrier, comprising of loosely attached thick mucus layer (28, 29), and cell 
surface bound glycoproteins that form the glycocalyx at the apical surface, protecting 
the epithelium from invading enteric pathogens (30-32). However, many pathogens, 
including ETEC, are equipped with multiple mucinases (33, 34) which degrade mucins 
and may allow their access to the apical glycocalyx.  
Glycosylation, a common form of post-translational modification present in all living 
beings, is essential for the synthesis of secreted and cell surface glycoproteins (35-37). 
One of the crucial steps in glycosylation is the formation of dolichol-phosphate-mannose 
(Dol-P-Man), an essential mannosyl donor for multiple glycosyl transferases. Dol-P-Man 
synthesis is carried out by a mannosyltransferase enzyme, dolichol phosphate mannose 
(DPM) synthase (38-40). DPM synthase consists of three subunits, DPM1, DPM2 and 
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DMP3, of which DPM1 is the active subunit (41) that catalyzes the reaction between 
dolichol-phosphate and GDP-mannose to generate Dol-P-Man. Dol-P-Man is essential 
for glycosyl phosphatidylinositol (GPI) membrane anchor synthesis, O- and N-
glycosylation, as well as mannosylation (38).  
ETEC adhesins characterized thus far are lectins that interact with different glycans 
presented on cell surface glycoconjugates (42-44). Therefore, host surface 
glycoproteins likely play vital roles in ETEC adhesion, and changes in host glycosylation 
processes could alter surface glycan presentation on epithelial cells to modulate ETEC-
host interactions. Cyclic-AMP influences glycoprotein secretion (45-48). Because LT 
increases host intracellular cAMP (9) and enhance ETEC adhesion to intestinal 
epithelium (49, 50), ETEC infection could modulate expression of host cell surface 
glycoproteins, favoring enhanced  interactions with host. Early studies reported that 
cAMP-dependent protein kinase A-mediated phosphorylation activates DPM1 
mannosyltransferase and thus increases Dol-P-Man formation (48, 51, 52), potentially 
supporting synthesis of mannosylated glycoproteins (40, 53). In addition, it has been 
reported that cAMP increases expression of GPI-anchored carcinoembryonic antigen-
related cell adhesion molecule-6 (CEACAM6), a receptor for the FimH adhesin of type 1 
pili (54).  As aype 1 pili of multiple E. coli interact with CEACAM6 (55, 56) and these pili 
facilitate ETEC interaction with intestinal epithelial cells (57), ETEC may also employ 
CEACAM6 for adhesion to host. 
Microbiota contribute significantly in protecting the intestinal epithelium from enteric 
infections (58). For successful colonization, ETEC must overcome the ‘colonization 
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resistance’ offered by resident microbiota (59). Additionally microbiota has profound 
effects on gut epithelial maturation and nutrition uptake (60, 61) and also actively 
participates in degradation of glycans present in the intestinal mucosa (62, 63), perhaps 
contributing in shaping the intestinal surface glycan structure. Therefore, since toxin-
induced intracellular cAMP stimulates mucosal glycoprotein synthesis and secretion 
(43, 45, 46), suggesting probable alteration of cell surface glycans, LT-mediated 
modification of host cell surface glycans could also alter the intestinal microbiota 
structure, and indirectly influence ETEC-host interactions. In this study we present data 
which support the hypothesis that LT alters cell surface glycoprotein presentation and 
thus influences FimH mediated ETEC-host interactions.         
RESULTS 
LT toxin alter expression of genes involved in glycosylation pathway 
Because LT treatment has been shown to enhance intestinal epithelial mucin production 
(43), and because mucins are heavily glycosylated, we questioned questioned whether 
the glycan profile of surface glycoproteins might also be altered following toxin 
exposure. To address this question we first examined the expression profile of the 
different genes involved in glycosylation pathways. RNAseq analyses were performed 
on Caco-2 intestinal cells treated with LT or mutant LT (mLT, inactivated by introduction 
of a point mutation, R192G) (64) and compared these to untreated cells. Cluster 
analysis based on Pearson distance did not show any difference in gene expression 
profile of cells treated with mLT and untreated cells, but cells treated with LT 
demonstrated differential expression of many genes, including genes involved in 
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glycosylation processes (Figure S1a-b). Intriguingly, expression of DPM1, which 
encodes the active enzymatic subunit of DPM synthase, was increased in LT-treated 
cells compared to either mLT-treated cells or untreated cells (Figure 1a, b). DPM1 
expression in cells treated with mLT or in untreated cells was comparable, suggesting 
that the enzymatic activity of LT is critical for increased expression of DPM1. We 
validated these RNAseq data by quantitative RT-PCR analyses (Figure 1b, inset). 
Consistent with the known effect of cAMP-dependent protein kinase (PKA) mediated 
phosphorylation and activation of DPM1 (51), we observed toxin dependent increase in 
DPM1 gene expression, supporting activation of glycoprotein synthesis pathways 
following LT treatment. 
Among other genes of dolichol-linked oligosaccharide precursor synthesis process, 
DOLK, DOLPP, ALG1, ALG2, ALG7 and ALG11 were also significantly increased in LT 
treated cells (Figure 1c). DOLK encodes dolichol kinase which phosphorylates ER 
membrane-anchored dolichol to generate dolichol-phosphate (Dol-p), followed by 
addition of two N-acetyl glucosamine residues facilitated by dolichol phosphate-N-
acetylglucosamine transferase encoded by ALG7, and N-acetylglucosamine 
transferases encoded by ALG13/ALG14. Subsequently, 5 mannose residues are added 
by mannosyl transferases, encoded by ALG1, ALG2 and ALG11 genes, yielding the 
initial glycan structure, Dol-pp-(GlcNAc)2-Man5, for further processing.   
Mannosidases are also involved in intermediary steps of the N-glycosylation pathway 
and changes in the activity of these enzymes might alter glycan composition (65, 66). 
Disruption of glycan processing by alpha-mannosidase alters glycosylation patterns (67, 
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68). Earlier we demonstrated that inhibition of α-mannosidase class 1 (MAN1A1) 
enzyme with kifunensine significantly increased surface expression of mannosylated 
glycoproteins on epithelial cells, allowing enhanced binding of mannose specific FimH 
adhesin and promoting ETEC adhesion (57). Interestingly, in RNAseq analyses, we 
observed decreased expression of two key mannosidase encoding genes, MAN1A1 
and MAN2A1, in cells treated with LT but not in cells treated with mLT (Figure 2a). The 
MAN1A1 mannosidase trims the alpha-1,2-linked mannose residues from 
Man9GlcNAc2 to produce Man5GlcNAc2 for further processing to hybrid and complex 
glycans (69, 70). The Man2A1 mannosidase catalyzes the first committed step in the 
biosynthesis of complex N-glycans, cleaving the alpha-1,3-linked and alpha-1,6-linked 
mannose residues of Man5GlcNAc2 to generate Man3GlcNAc2 core structure for 
complex glycan synthesis (71, 72). Therefore, decreased expression of these two 
mannosidase genes could significantly alter cell surface glycan architecture.  
LT favors presentation of highly mannosylated surface glycans 
Because LT modulates expression of multiple enzymes involved in glycosylation 
pathways, these changes will likely impact glycan structure of surface glycoproteins. 
Therefore, we examined the surface glycan pattern of intestinal cells treated with LT or 
mLT and compared with untreated cells. N-glycans expressed on intestinal cell surfaces 
were recovered and analyzed by nano-LC/MS, revealing a shift toward more heavily 
mannosylated glycans in cells treated with LT than in cells treated with mLT or 
untreated cells (Figure 2b). Similarly, ETEC infection induced surface expression of high 
mannose glycoproteins, as we observed significant increases in high mannose glycan 
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content in cells infected with ETEC than in uninfected cells (Figure 2c). In line with these 
observations, binding of Galanthus nivalis agglutinin (GNA), a mannose lectin (73), was 
enhanced when cells were treated with LT compared to untreated cells. Therefore, 
these data strongly suggest LT increases expression of mannosylated glycoproteins on 
intestinal epithelial cells.  
LT alters expression of CEACAMs on intestinal epithelial cells  
Glycoproteins of the CEACAM family, including CEACAM1, CEACAM5, CEACAM6 and 
CEACAM7, are integral part of the intestinal glycocalyx (74, 75). Of these, CEACAM5 
and CEACAM6 are mannosylated glycoproteins (55). Intriguingly, RNAseq analyses of 
Caco-2 cells treated with LT demonstrated altered expression of multiple genes of the 
CEACAM family (Figure 3a). While expression of CEACAM18 and CEACAM19 genes 
were decreased, expression of CEACAM1, CEACAM5, CEACAM6 and CEACAM7 
genes were significantly increased in cells treated with LT compared to cells treated 
with mLT or in untreated cells. To validate CEACAM5 and CEACAM6 upregulation, we 
examined the expression of these genes by quantitative RT-PCR (Figure 3b). The 
expression of both CEACAMs was indeed increased in LT-treated cells compared to 
untreated cells or those treated with mLT, suggesting that the enzymatic activity of the 
toxin is necessary for induction of these CEACAMs. In agreement with these 
transcription data, increased amounts of CEACAM5 and CEACAM6 were detected 
using monoclonal antibodies specific to CEACAM5 (not shown) and CEACAM6 (Figure 
3c, top panel). Similarly, we observed increased CEACAM6 production following 
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forskolin induction of cAMP, supporting a role for this second messenger in modulating 
glycoprotein expression (Figure 3c, bottom panel).  
ETEC interacts with intestinal CEACAM6 
Because earlier studies demonstrated that E. coli binds to mannosylated CEACAM6, we 
hypothesized that LT-induced enhancement of CEACAM6 expression in intestinal 
epithelial cells might facilitate ETEC adhesion. Intriguingly, cells infected with ETEC 
demonstrated localized increases in expression of CEACAM6 around adherent ETEC 
(Figure 4a). Since FimH interacts with CEACAM6 and ETEC utilize FimH mediated 
interaction for adhesion, increased expression of CEACAM6 around ETEC could 
facilitate adhesion. To examine the contribution of CEACAM6 in ETEC adhesion, we 
used CRISPR-Cas9 to generate Caco-2 cells lacking CEACAM6 (CEACAM6-/-). After 
validating CEACAM6 deletion (Figure 4b), we assayed GNA lectin binding to the 
CEACAM6-/- cells (Figure 4c). As expected, significant reduction of GNA binding was 
observed to CEACAM6-/- cells compared to parent Caco-2 cells (CEACAM6+/+). 
Interestingly, LT treatment of CEACAM6-/- cells increased GNA binding, suggesting that 
LT induces other mannosylated glycoproteins on CEACAM6-/- cells. ETEC adhesion to 
CEACAM6-/- cells was significantly reduced compared to parent Caco-2 cells, while 
fimH mutants to CEACAM6-/- and CEACAM6+/+ cells was comparable (Figure 4d), 
implying that ETEC interaction with CEACAM6 is probably FimH mediated. Additionally, 
in line with GNA binding data, adhesion of WT ETEC to CEACAM6-/- cells was 
significantly higher than fimH mutant, suggesting that FimH of ETEC may also interact 
with other mannosylated proteins present on CEACAM6-/- cells.  
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FimH mediated interactions influence ETEC colonization of mouse intestine 
In order to investigate the contribution of FimH in intestinal colonization by ETEC, we 
first examined the colonization dynamics of fimH mutants in mice. CD1 mice were 
infected with either fimH mutants or wild type ETEC (WT), and at 24 hrs post infection 
intestinal colonization in different niches including jejunum, ileum, colon and feces was 
examined. In mice infected individually with WT or the fimH mutant, intestinal 
colonization was comparable (Figure 5a). Likewise, comparable levels of ETEC 
shedding were observed in feces of WT or mutant infected mice (Figure 5a). Additional 
groups of mice were infected with either the WT or fimH mutant and observed over 10 
days post infection for fecal shedding. No significant difference was observed in overall 
fecal shedding between fimH mutant and WT over the follow-up period (Figure 5b). 
Fecal shedding of both WT and fimH mutants fell steadily over a week, demonstrating 
typical self-limiting colonization of ETEC (76). Interestingly however, in competition 
assays where mice were co-infected with fimH mutant and WT, we observed increased 
colonization and shedding of the fimH mutant relative to the WT (Figure. 5c).  
Intestinal microbiota influence FimH-mediated colonization 
The intestinal lumen is heavily colonized by microbiota (77), which inhibit the 
colonization of invading intestinal pathogens (58, 78). Some members of the microbiota 
degrade glycans found in host mucus secretions or shed epithelial cells (79) that could 
change the availability of intestinal glycans and impact pathogen-host interactions. 
Therefore, the streptomycin treatment in our standard infection protocol, which reduces 
intestinal microbiota, could affect pathogen-host interactions. To test this, intestinal 
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colonization by fimH mutant was examined in mice treated with or without streptomycin. 
As predicted, overall colonization of both WT ETEC and fimH mutant were decreased in 
untreated mice, as we recovered significantly fewer bacteria in the feces from untreated 
mice than from streptomycin treated mice (Figure 6a). These findings are in agreement 
with the inhibitory role of microbiota in ETEC colonization. Intriguingly, in competitive 
colonization assays, we observed that intestinal colonization of mice (both streptomycin 
treated and untreated) by fimH mutant was more than WT ETEC (Figure 6b).  
We further tested the impact of intestinal microbiota on FimH mediated colonization by 
ETEC. For this, mice were co-infected with ampicillin resistant WT and fimH mutant in 
competitive colonization assays. To control intestinal microbiota, ampicillin was supplied 
in the drinking water as indicated. High colonization titers of both WT and fimH mutant 
were maintained over the initial ampicillin treatment period (days 1-14) (Figure 6c). 
However, removal of ampicillin treatment rapidly decreased ETEC colonization (days 
14-21), suggesting recovery of microbiota which perhaps inhibited ETEC colonization. 
Re-administration of ampicillin, however, reinstituted ETEC colonization (days 21 to 35). 
Intriguingly, during this period we observed significantly less shedding of the fimH 
mutant than the WT ETEC, and a lower competitive index of fimH mutant over WT 
ETEC (Figure 6d), implying possible contribution of FimH in ETEC colonization in the 
presence of microbiota.           
Increased expression of multiple adhesion related genes in fimH mutants 
recovered from mice 
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To begin to understand the determinants of increased colonization of fimH mutants in 
co-infections, we examined the expression profile of genes that were known to be 
involved in ETEC colonization. For this, we performed RT-PCR analyses on fecal 
samples collected from mice infected with WT or fimH mutants. Intriguingly, we detected 
increased expression of multiple genes, including fimA, and cfaB that encode the major 
structural subunit of type 1 pili and CFA/I fimbriae, respectively (Figure 7a). Additionally, 
we examined fimbrial production of the fimH mutants. Using electron microscopy we 
observed that while the majority of the fimH mutant bacteria were non-fimbriated (Figure 
7b), some cells in this population were extensively fimbriated (Figure c). Examination of 
pili prepared from both bacterial cultures showed a major pilin subunit (Figure 7d). 
However, only pili prepared from WT were reactive to anti-type 1 pili antibody on 
immunoblots (Figure 7d), indicating that fimH mutant are making other pili. Mass 
spectrometry analysis of the fimbrial preparation from the fimH mutant identified CfaB, 
the major structural subunit of CFA/I fimbriae, suggesting that fimH mutants are 
producing CFA/I fimbriae. In addition to these fimbrial genes, we detected increased 
expression of pqiB which encodes a homologue of the multivalent adhesion molecule 7 
(Mam7) (Figure 7a). Mam7 is important for adhesion (80, 81) and pathogenesis of many 
Gram-negative pathogens including Vibrio cholerae and enteropathogenic E. coli (81). 
Therefore, these data support the idea that relative to WT ETEC fimH mutants 
overexpress multiple adhesion related genes.  
Altered expression of adhesion related genes in fimH mutants promotes 
enhanced colonization of mice 
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Increased expression of multiple adhesion related genes could transform fimH mutant 
into a better colonizer than WT ETEC in mice. To investigate whether enhanced 
expression of different adhesion related factor(s) were involved in increased 
colonization of fimH mutants, we generated multiple mutants by sequential deletion of 
genes that were overexpressed in fimH mutants. Analogous to FimH of type 1 pili, CfaE 
is the tip adhesin of CFA/I fimbriae required for interactions (82) and pqiB encodes a 
Mam7 adhesin. Therefore, we tested fimH-cfaE and fimH-pqiB double mutants, as well 
as fimH-cfaE-pqiB triple mutants, in competitive colonization experiments with WT. 
Surprisingly, like fimH mutants, both fimH-cfaE and fimH-pqiB double mutants also 
outcompeted WT ETEC in competitive colonization of mice (Figure 8). Interestingly, 
however, fimH-cfaE-pqiB triple mutants colonized less efficiently than WT ETEC (Figure 
8). Therefore, increased expression of CFA/I fimbriae and homologue of Mam7 adhesin 
in fimH mutants could account for increased colonization of mice by the fimH mutant. 
Overall, these experiments demonstrate the enormous complexity of ETEC-host 
interactions during pathogenesis.   
DISCUSSION 
Enterotoxigenic E. coli adhere to and colonize intestinal epithelia where these bacteria 
deliver LT and/or ST to cognate receptors (9). Delivery of these toxins to target 
epithelial cells requires direct host contact (83). Like other pathogenic E. coli, ETEC are 
equipped with numerous variety of virulence factors that include both highly conserved 
(21, 34) as well as pathotype-specific features (33). Included among these virulence 
factors are adhesins (20, 43, 57, 84) that enable ETEC to make the necessary contact 
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with host for toxin delivery. Since adhesins are mostly lectins that recognize glycan 
structures of glycoconjugates, modification of host cell surface glycoproteins could 
influence ETEC-host interactions. Collectively, data presented here suggest that LT 
modifies host glycosylation processes and enhances expression of highly mannosylated 
cell surface glycoproteins that could influence ETEC interactions with intestinal 
epithelium. These findings support recent observations of ETEC-induced changes in 
target cells to enhance interactions with the host (43, 85).  
Because cAMP is a second messenger in myriad cell signaling pathways (86) and 
activates PKA that phosphorylates any protein with an exposed R-X-X-pS/T motif (87), 
LT-induced cAMP could possibly, directly and/or indirectly, stimulate multiple host 
responses (86, 88, 89), including glycosylation processes. Indeed, data obtained from 
RNASeq and mass spectrometric analyses demonstrated that, in addition to targeting 
host glycosylation processes, LT also enhances expression of multiple cell surface 
glycoproteins, including carcinoembryonic antigen-related cell adhesion molecules 
(CEACAMs).  
CEACAMs, including CEACAM1, CEACAM5 (also known as CEA or CD66e), 
CEACAM6 (also known as NCA or CD66c) and CEACAM7 are highly glycosylated 
constituents of the intestinal apical glycocalyx (74, 75) and influence pathogen-host 
interactions (56, 90-93). Interestingly, the FimH adhesin of type 1 pili of E. coli binds to 
CEACAM6 (54, 55, 92). Our observations of increased CEACAM6 expression following 
LT treatment and  FimH-mediated ETEC association with CEACAM6 (Figure 4) inform a 
novel interaction of ETEC infection that might influence the outcome of these 
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interactions. Since intestinal CEACAM6 is distributed in multiple locations- membrane 
bound on epithelial cells or on microvesicles, in filaments making up the glycocalyx of 
intestinal epithelium, and as secretory components of goblet cells secreted together with 
mucins (94), ETEC interactions with these different forms of CEACAM6 could therefore 
impact ETEC adhesion. For example, while attachment to cell bound CEACAM6 may 
confer adhesion, attachment of ETEC to unbound CEACAM6 could facilitate clearance 
from the intestine. Since cAMP enhances goblet cell secretion (89), LT could increase 
secretion of luminal CEACAM6 that might serve as decoy receptor. Consequently, 
enhancement of CEACAM6 production following LT treatment could be a host defense 
mechanism. Alternatively, ETEC could use these interactions to facilitate adhesion with 
host at the early stages of infection, as the infection progress, LT-induced induction 
might increase secreted CEACAM6 that ETEC could exploit to detach from the host and 
exit in the stool to start the next round of infection. Therefore, although FimH-CEACAM6 
mediated interactions facilitate colonization of human ileum by AIEC (54, 95), the 
contribution of this interaction for ileal colonization by ETEC is yet to be fully 
understood. 
In theory, alteration of the intestinal glycan landscape following ETEC infection could 
perturb composition of the microbiota and hinder intestinal homeostasis, including 
nutrient absorption. Indeed, ETEC infections are associated with malnutrition in children 
(3), and recently, one study reported that ETEC as well as Vibrio cholerae infections 
alter intestinal microbial community structure (96). Since microbiota degrade mucosal 
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glycoproteins (97), presence or absence of microbiota could change the architecture 
and availability of intestinal glycans, and thereby impact ETEC-host interactions.  
In order to cause infection, enteric pathogens must breach host innate defense 
mechanisms and overcome microbiota-exerted inhibition of colonization, which ETEC 
accomplish by employing multiple virulence factors (18-20, 33, 34, 43). Deletion of any 
of these factors compromises the dynamics of ETEC-host interactions. While the 
increased intestinal colonization of mice by fimH mutant observed in the present study 
is counterintuitive, our studies suggest that ETEC are equipped with mechanism(s) to 
overcome the loss of FimH activity. Importantly, we detected overexpression of multiple 
adhesion factors, and identified induction of a novel Mam7 adhesin of ETEC in fimH 
mutants recovered from feces, supporting the hypothesis that ETEC possess 
functionally complemented factors and/or regulatory mechanisms to optimize infection. 
Together, these data illustrate the  complexity of ETEC colonization which involves 
ETEC, host and the resident microbiota. On the other hand, the relevancy of intestinal 
colonization data obtained from mice to the human host is limited by several factors: 
first, mice do not make CEACAM6, second, intestinal mucins produced by mice and 
humans are somewhat different, and third, intestinal microbiota as well as diet are also 
different, and may affect intestinal glycan content. For all these reasons, the mouse 
model may not capture all the ETEC-host interactions presented during human 
intestinal colonization.  
In summary, we identified several novel ETEC host interactions, including modification 
of host glycosylation pathways, and detected interaction between a highly conserved 
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FimH adhesin and host CEACAM6 in ETEC pathogenesis, suggesting a mechanism for 
LT-mediated enhancement of ETEC adhesion. Additionally, found that Mam7 adhesin 
might participate in ETEC-host interactions. Data presented here also suggest intricate 
interactions between ETEC and intestinal microbiota during colonization. Overall, the 
findings described here underscore the highly complex nature of ETEC-host interactions 
and expand our understanding of ETEC pathogenesis in ways that foster rational 
vaccine design approaches that target these globally important pathogens. 
METHODS 
Cell culture and treatment 
Caco-2 intestinal cell (ATCC) culture was maintained in MEM media supplemented with 
20% FBS. In order to investigate the effect of LT toxin on intestinal epithelial cells, 
Caco-2 cells were seeded at ~0.5 x105 cells/well of 96-well cell culture plate in MEM 
media supplemented with 20% FBS (Gibco). Cells were grown at 37˚C in incubator with 
5% CO2 for 4 days with media changed every 2 days. Cells were treated with different 
toxins, including, holotoxin (LT), mutant toxin (mLT) and B subunit of LT (LTB), by 
replacing the culture medium with fresh medium supplemented with 0.1 µg/ml final 
concentration of toxin. Following overnight treatment, cells were washed with pre-
warmed PBS and processed for subsequent analysis.   
RNA isolation, cDNA synthesis and RT-PCR  
Caco-2 cells treated with toxins were processed for RNA extraction using illustra 
RNAspin mini (GE Healthcare) RNA extraction kit. cDNA synthesis was done using 
SuperScript VILO cDNA synthesis kit (Invitrogen) by using 0.1 µg of total RNA. Equal 
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amount of cDNA was used to perform RT-PCR for comparative expression analysis. All 
reactions were performed in triplicate, including GAPDH control, using SYBR Green 
based master mix (Thermo Fischer) and samples were run on Applied Biosystems® 
7500 Real-Time PCR System (Applied Biosystem) and analyzed with ViiA7 software 
(v1.2.4). Normalized expressions were calculated by ∆CT method. 
Mutagenesis and knock out 
Double mutant and triple mutant (table 1) were constructed using lambda red mediated 
recombination as previously described (98). To construct fimH-cfaE and fimH-pqiB 
double mutant gene cfaE and pqiB, respectively, were deleted and for fimH-cfaE-pqiB 
triple mutant gene cfaE and pqiB were deleted sequentially from the fimH mutant. For 
deletion of cfaE gene primers jf101413.7 and jf101413.8 and for deletion of pqiB gene 
primers jf060716.1 and jf060716.2 (table 2) were used to amplify the kanamycin 
resistance cassette from pKD4 plasmid with 60-bp tails corresponding to the DNA 
sequence immediately upstream and downstream of respected genes. The resulting 
amplicon was then introduced into fimH carrying the pKD46 helper plasmid for lambda 
red-mediated homologous recombination and mutants were selected on 50 μg/ml 
Kanamycin containing LB-agar plate and screened for mutant by PCR. In order to 
delete CEACAM6 we used CRISPR/Cas gene modification system, generating 
CEACAM6-/- cells. 
Type 1 pili extraction and detection 
Bacteria culture, grown in type 1 pili inducing conditions, was processed for pili 
extraction by following a previously described method (57). Pili extracts were separated 
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on SDS-PAGE minigel (Bio-Rad) and either stained with SYPRO Ruby protein gel stain 
(Invitrogen) or transferred to nitrocellulose membranes (Bio-Rad) using a Mini Trans-
Blot electrophoretic cell (Bio-Rad) for 60 min at 100 V. Following blocking with 5% milk-
PBS supplemented with 0.05% Tween 20 (Pierce), the membrane was incubated with 
anti-type 1 pili primary raised in rabbit (1:5,000) and HRP conjugated anti-rabbit 
secondary (1:5,000) antibodies. Chemiluminescent substrate (Clarity Western ECL 
substrate, Bio-Rad) was used for detection. 
Adhesion assay 
Bacteria were grown at type 1 pili inducing conditions as described previously (57). For 
adhesion assay, cultures were diluted at 1:10 in pre-warmed cell culture media before 
infecting cells. Inoculums were serially diluted and plated on Luria agar for CFU count. 
Following inoculation cells were incubated at 37°C and 5% CO2 for 1 h, washed with 
pre-warmed tissue culture medium 3 times with gentle shaking (100 rpm) for 1 min 
each. Infected cells were then lysed in 0.1% Triton X-100 for 5 min, and the cell 
associated bacteria were recovered by plating lysates onto Luria agar for CFU count 
and expressed as percent cell associated bacteria. 
Fluorescence microscopy 
In order to investigate ETEC association with CEACAM6 polarized epithelial cell 
cultures, grown on trans-well filter, were infected with WT or fimH mutant ETEC. 
Following infection, cells were washed 3 times with pre-warmed tissue culture medium 
with gentle shaking (100 rpm) for 1 min each to remove unbound bacteria (57). Cells 
were then fixed with 4% paraformaldehyde for 30 min at room temperature (RT), 
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washed with 3 times with PBS and blocked with 1% BSA-PBS for 30 min at RT. Anti-
CEACAM6 monoclonal antibody raised in mouse (Santa Cruz) and anti-O78 antibody 
raised in rabbit were used for detection of CEACAM6 and bacteria, respectively. 
Fluorescent conjugated anti-mouse and anti-rabbit secondary antibodies were used to 
visualize CEACAM6 and cell associated bacteria by fluorescent microscopy.  
Transmission electron microscopy  
For negative staining, bacteria were allowed to absorb onto glow discharged 
formvar/carbon-coated copper grids for 2 min.  Grids were then washed with PBS, fixed 
with 1% glutaraldehyde, and stained with 1% aqueous uranyl acetate (Ted Pella Inc., 
Redding CA) for 1 min.  Excess liquid was gently wicked off and grids were allowed to 
air dry.  Samples were viewed on a JEOL 1200EX transmission electron microscope 
(JEOL USA, Peabody, MA) equipped with an AMT 8 megapixel digital camera 
(Advanced Microscopy Techniques, Woburn, MA). 
Mouse intestinal colonization 
To investigate the contribution of FimH mediated ETEC-host interactions in colonization, 
mice were challenged with ETEC as previously described (50). Briefly, 5-8 week old 
female mice (CD1) were pretreated with streptomycin (5 g/liter) in drinking water for 24 
h to suppress microbiota mediated colonization resistance (99), unless otherwise 
stated. For single infection mice were inoculated with either WT or fimH mutant by oral 
gavage. Another group of mice were co-infected with WT and fimH mutant mixed at 1:1 
ratio. To examine the influence of streptomycin treatment on FimH mediated 
interactions, a group of untreated mice were also co-infected. Mice were sacrificed at 
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specified times, different intestinal sections were collected and lysed in 5% saponin, and 
lysates were plated for CFU count. Since fecal shedding reflects intestinal colonization, 
for colonization kinetics, fecal samples were collected every day for 10 days from a 
group of single infected mice. To investigate the contribution of microbiota on FimH 
mediated interactions, mice infected with WT and fimH mutant (both strains harboring 
plasmid with ampicillin resistant gene) were continuously treated with ampicillin (100 
mg/liter) in drinking water for 2 weeks, followed by 1 week of without ampicillin 
treatment to allow microbiota recovery, followed by additional 2 weeks of ampicillin 
treatment. Fecal samples were collected at different days as indicated, for CFU count. 
Bacterial gene expression analysis 
Fresh fecal samples from mice infected with either fimH or WT ETEC were collected in 
PBS on ice, resuspended and centrifuged at 350 × g to remove debris. A 500 µl of 
suspension was mixed with equal amount of Trizol (Invitrogen) and stored immediately 
at -80˚C. RNA was isolated per manufacturer’s protocol and cleaned up using RNeasy 
kit (Qiagen), followed by DNAse I digestion. Conventional PCR for arcA (a 
housekeeping gene) was used to confirm the removal of DNA (data not shown). cDNA 
synthesis and RT-PCR were done as above.
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CHAPTER THREE: TABLES 
Table 1: List of strains used 
Strain 
designation 
Genotype Description Reference 
H10407 wild type ETEC serotype 078:H11, LT+LST+ (100) 
jf2944 fimH::kan 
fimH; fimH gene is replaced with 
kanamycin resistant gene  
(57) 
jf2945 
fimH::kan, 
cfaE::cm 
fimH-cfaE double mutants; fimH gene 
is replaced with kanamycin resistant 
gene and cfaE gene is replaced with 
chloramphenicol resistant gene 
(57) 
jf4674 
fimH::kan, 
pqiB::cm  
fimH-pqiB double mutants; fimH gene 
is replaced with kanamycin resistant 
gene and cfaE gene is replaced with 
chloramphenicol resistant gene 
This study 
jf2944 
∆fimH, 
cfaE::kan, 
pqiB::cm 
fimH-cfaE-pqiB triple mutants; fimH 
gene is deleted and cfaE gene is 
replaced with kanamycin resistant 
gene and pqiB gene is replaced with 
chloramphenicol resistant gene  
This study 
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Table 2: List of primers 
Mutagenesis primers 
Primers Sequence Description 
jf062116.1 GAATTTGTAAAGAACCCACGT
GTGCAGGATTTGCTGGCAAAG
AATGATAAAGGATAAACGGTT
TAAACGATATCGGATCCA 
Forward, cfaE deletion primer; 60 
nucleotides homology tail 
immediately upstream from cfaE. 
nucleotide sequence of cat gene 
jf062116.2 TTAACAAACAGATTACCTATTT
ACAATATTGGCGCGCAATAGC
GCCAATATTGTTGTTATACTAG
TATTACCCTGTTATCC 
Reverse, cfaE deletion primer; 60 
nucleotides homology tail 
immediately downstream from cfaE. 
nucleotide sequence of cat gene 
jf060716.1 ATGAGTCAGGAAACGCCCGCT
TCGACGACTGAAGCGCAGATT
AAAAATAAACGCCGTATCGTT
TAAACGATATCGGATCCA 
Forward, pqiB deletion primer, 60 
nucleotides homology tail 
immediately upstream from pqiB. 
nucleotide sequence of cat gene 
jf060716.2 TTATTTGGGAAGCGCAGTACC
CCATTCACGCCACTCTTTCGG
TTCACTTTCCTGCAACAGACT
AGTATTACCCTGTTATCC 
Reverse, pqiB deletion primer; 60 
nucleotides homology tail 
immediately downstream from pqiB. 
nucleotide sequence of cat gene  
RT-PCR primers 
Gene Primer sequences 
Bacteria Forward Reverse 
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etpA TACCGTGTTCATCAGCATACC GGTGACAGGAGATGTGGTTAAT 
fimH GTGATGTTTCTGCTCGTGATG GTTGTGCCGGAGAGGTAATA 
cfaB GAGTGCTTCAGCAGTAGAGAAA TGATGCGGGAGAATAAGCTAAC 
eatA 
CACCAATCTGAACGTGGGTATA
G TTACGGGATAGTCAGGGAGATG 
fimA GCTGGATGGTGCGTCATTTA GCATTAGCAGCACCTGGGGTTG 
eaeH GAAGGATGCGTACGGGAAC CCGCTAAACACTGGTGCAT 
matA CATCACGGTATCGCCAGTTT GGTCTATTTGACGTGGCTATCG 
ybgD ATCGCTGTGATGTGACTGATTA GCTATTCACTGCACCTGTTTAT
G 
yadN CGTTGGCGCTAAAGCTAAAC AGCGATATTAACGCCGTCAG 
yehD AAGGCGATAGCCAGTAGCAA CCACACGCATAACCAGAGAA 
yraH GATAATGGCACCGTCCCTAA CGGGATCTGATAAACCGTGT 
yfcV GTTCCGGACGATCACAAACT GCCGCTATTTGCAGAAGAAA 
pqiB TCGTAAACTCACCAGCAAAGG AGAAACTCAACGCCATCCAG 
arcA CGAAATCGGTGCAGATGAC TGCACGAATCGTCAGTTCA 
Human 
CEACAM6 CACCGTCGGCATCACGA GAAGAATTCAGGGTCTGGTCCA 
DPM1 ATGGATGCTGATCTCTCACACC CCATTTCCTTTGTAGCGAGTTC 
GAPDH TGACAACGAATTTGGCTACAGC TGATGGTACATGACAAGGTGC 
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CHAPTER THREE: FIGURES 
 
Figure 1. LT modulate transcription of genes involved in glycan synthesis 
pathway.  
a) Schematic diagram of glycan precursor synthesis pathway. Enzymes involved in the 
different steps of the pathway are shown in blue. b) RNAseq data showing expression 
of different subunit of DPM synthase in cells treated with holotoxin (LT), mutant toxin 
(mLT) or untreated (). Each bar represents mean FPKM (Fragments Per Kilobase of 
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transcript per Million mapped reads) value of duplicate samples. Inset showing RT-PCR 
analysis of active subunit, DPM1, of DPM syntahse. Bar represents % gene expression 
normalized to GAPDH (n=3). c) RNAseq analysis of genes involved in glycan precursor 
formation. Bar represent mean±SD of duplicate samples.    
  
118 
 
 
Figure 2. LT modify host glycan synthesis towards high mannose glycan.  
a) Transcription analysis of different mannosidase enzymes involved in glycosylation 
process. Data showing FPKM value generated from RNAseq analysis of cells treated 
with holotoxin (LT), mutant toxin (mLT) or untreated (). Bar represent mean±SD of 
duplicate samples. b) Mass spectrometric analysis of surface expressed mannosylated 
glycans recovered from intestinal cells treated with LT or from untreated cells (control). 
Pie chart presenting changes in abundance of different mannosylated glycans following 
LT treatment. c) Types of mannosylated glycans recovered following ETEC infection. 
Number indicates fold change in abundance relative to uninfected cells. d) Data 
showing mannose specific GNA lectin binding to cells treated with LT. Bar represents 
mean±SD (n=5). P value was calculated by nonparametric Mann-Whitney test. *p<0.05.  
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Figure 3. LT enhance intestinal CEACAMs expression.  
a) Transcriptional profile of CEACAMs of intestinal cells treated with holotoxin (LT), 
mutant toxin (mLT) or untreated control (). Bar represent mean FPKM value generated 
from RNAseq analysis with standard deviation of duplicate samples. b) Gene 
expression analysis of CEACAM5 and CEACAM6 by RT-PCR. Data represents % gene 
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expression normalized to GAPDH (n=5). Bar represent mean±SD. P values were 
calculated by nonparametric Mann-Whitney test. ***p<0.0001. c) Images shown are 
CEACAM6 from cells following treatment with LT, toxin B subunit (LTB), mLT or 
untreated (), detected on immunoblot using anti-CEACAM6 monoclonal antibodies 
(top). Bottom image showing CEACAM6 from cells treated with different amount of 
forskolin. Tubulin was used as loading control.   
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Figure 4. CEACAM6 expression enhance FimH mediated ETEC adhesion. 
a) Confocal microscopic images of polarized culture of Caco-2 cells infected with WT 
ETEC, showing expression of CEACAM6 (anti-CEACAM6 monoclonal, red) and cell 
associated ETEC (anti-O78, green). Insets are magnified (6× digital) images showing 
induction of CEACAM6 expression around ETEC. b) Evaluation of CEACAM6-/- Caco-2 
cells for the loss of CEACAM6 expression. Nuclei were stained with DAPI (blue) and α-
CEACAM6 (red). c) GNA lectin biding to CEACAM6-/- cells following LT treatment. Bar 
represent mean±SD (n=5). P values were calculated by nonparametric Mann-Whitney 
test. **p<0.001. d) Adhesion of WT and fimH mutant to CEACAM6-/- cells. Horizontal 
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dashed line represent mean of duplicate experiments. P values were calculated by 
nonparametric Mann-Whitney test. ***p<0.0001. 
 
Figure 5. Dynamics of intestinal colonization of fimH mutants. 
a) Comparison of mouse intestinal colonization of fimH mutants and WT ETEC at 
different niches 24 hrs post infection. Open circle represents WT and closed circle 
represents fimH mutant. Horizontal line represents geometric mean. b) Kinetics of 
123 
 
intestinal colonization evaluated by fecal shedding. Fecal specimens were collected 
every day for 10 days post infection for CFU count of fimH mutant and WT ETEC. Open 
circle represents WT and closed circle represents fimH mutant. c) Data represent 
competitive index (CI) of intestinal colonization of fimH mutant over WT. Mice co-
infected with both strains were sacked at day 1 (n=10), day 2 (n=10) or day 3 (n=10) 
post infection for analysis of competitive colonization. 
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Figure 6. Antibiotic treatment affect FimH mediated colonization of ETEC in mice.  
a) Graph showing fecal shedding of WT and fimH mutant from streptomycin treated 
mice (blue) and untreated mice (green). Data expressed as per mg of feces. Open 
circles represent data from WT and closed circles represent data from fimH mutant. 
Horizontal line represents geometric mean. b) Competitive index (CI) of intestinal 
colonization of fimH mutant over WT from mice treated with streptomycin (blue) and 
from untreated mice (green). c) Fecal shedding kinetics of WT and fimH mutant in the 
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presence or absence of ampicillin. Each circle represents mean±SEM of CFU per mg of 
feces from mice infected with WT (blue) or fimH mutants (black). P values were 
calculated by nonparametric Mann-Whitney test. *p<0.05 and **p<0.001. b) Competitive 
index (CI) of intestinal colonization of fimH mutant over WT from mice treated with 
streptomycin (blue) and from untreated mice (green). Dashed line represents CI of 1. 
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Figure 7. Altered expression of adhesion related genes in fimH mutants.  
a) Transcription analysis of fimH mutants and WT ETEC collected from fecal samples. 
Each gene expression was normalized to housekeeping gene arcA and data presented 
as mean fold change. b) Evaluation of pili expression pattern of fimH mutants and WT 
ETEC counted under electron microscopy. At least 150 bacteria were evaluated per 
sample. c) Transmission electron microscopic images of WT ETEC and fimH mutants 
showing pili expression. d) Sypro ruby stained gel image of pili preparations from WT 
and fimH mutants ran on 4-15% gradient SDS-PAGE gel (top). Immunoblot of pili 
preparations from WT and fimH mutant showing anti-FimA reactivity to pili preparation 
from WT only (bottom).    
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Figure 8. Mouse intestinal colonization of different mutants. 
Competitive indices (CI) of fimH single mutant, fimH-cfaE and fimH-pqiB double mutant 
and fimH-cfaE-pqiB triple mutant vs WT ETEC. Each group of mice was co-infected with 
mutant and WT, and 24 hrs post infection mice were sacrificed for CFU count. Shown in 
plot is colonization to different intestinal niches, including fecal shedding. Each circle 
indicate datum from single mouse. Horizontal lines indicate mean CI (n=10 per group). 
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CHAPTER THREE: SUPPLEMENTARY DATA   
 
S1 Figure. Differential expression of genes involved in glycosylation pathway. 
a) Cluster analysis based on Pearson distance. Cells were treated with either holotoxin 
(LT) or mutant toxin (mLT) or untreated (). Duplicate samples were run for each 
treatment. Cells treated with mLT and untreated cells were clustered together, 
therefore, used as control for differential expression analysis. b) Dot plot showing 
differential expression of genes involved in glycosylation process. Gene expression with 
more than 1.5 fold changes were shown in red, between 1.5-0.7 fold changes were 
shown in black and less than 0.7 fold changes were shown in green. 
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Conclusion and Future Directions 
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4.1 Summary of the thesis 
This thesis investigated the contribution of type 1 pili mediated pathogen-host 
interactions to ETEC pathogenesis. We found that FimH mediated interactions 
enhanced ETEC adhesion to intestinal cells and promoted efficient delivery of LT and 
ST enterotoxins (1). We also investigated host responses to LT in the context of 
pathogen-host interactions. In an ongoing collaborative effort, using RNAseq and mass 
spectrometric analyses, we showed that LT responses modified host glycosylation 
processes and enhanced expression of CEACAM6, a receptor of FimH. We also found 
that in response to deletion of fimH ETEC enhanced expression of other adhesion 
molecules, leading to increased intestinal colonization of mice.  
These findings support a model in which FimH of type 1 pili interacts with mannosylated 
receptors of intestinal epithelium, promoting ETEC-host interactions and effective 
delivery of toxins that subsequently modulates host glycosylation processes and 
enhances CEACAM6 expression, changes which may further consolidate type 1 pili-
mediated interactions with host (Fig 1). Overall, studies in this thesis corroborated the 
role of highly conserved type 1 pili of ETEC in pathogenesis and identified novel ETEC-
host interactions.           
 
4.2 Identification of an uncharacterized adhesion factor  
Since fimH mutants were significantly more efficient in colonization of the murine 
intestine than WT ETEC, and the pqiB gene expression was elevated in the fimH 
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mutant strain, recovered from mouse feces, we speculated that increased expression of 
pqiB could contribute to colonization. To test this hypothesis, we examined both fecal 
shedding and mouse small intestinal colonization of an isogenic pqiB mutant 
(pqiB::CAT). Interestingly, in competition experiments, fecal shedding of the pqiB 
mutant was significantly diminished relative to WT ETEC (Fig 2a), a finding 
commensurate with impaired intestinal colonization of the intestine by the mutant (Fig 
2b), suggesting that PqiB contributes to intestinal colonization by ETEC.  
The pqiB gene was first found to be induced under oxidative stress, when Koh and Roe 
used a random promoter library screening technique to identify promoters induced with 
organic compound paraquat (2, 3). They identified a promoter upstream of an operon 
consisting of two genes named paraquat inducible A (pqiA) and B (pqiB) (2). They also 
showed that the promoter was under SoxRS regulon, as they detected decreased 
activity of the promoter in both soxR and soxS mutants (2). SoxRS may regulate 
expression of pqiAB, which encodes PqiA and PqiB, allowing E. coli to respond against 
oxidative stress they might encounter in the environment or inside the host (4-6). To 
investigate whether ETEC express PqiB, we first cloned the pqiB sequence of ETEC 
H10407 as in-frame with a myc-his tag sequence to construct ppqiB-myc-his expression 
plasmid, inserted in E. coli TOP10 for expression and purification of the protein. 
Recombinant PqiB-Myc-His protein expression was verified on anti-Myc immunoblotting 
(Fig 3a), and surface expression of Myc-tagged PqiB on TOP10 was detected by 
immunofluorescence microscopy (Fig 3b). Similarly, we detected PqiB expression in 
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ETEC H10407 grown in Luria broth (LB) (Fig 3c), however, H10407 growth in the 
presence of paraquat did not appear to enhance PqiB expression (Fig 3c). Deletion of 
pqiB did not have an appreciable effect on ETEC growth in LB (Fig 3d), and pqiB 
mutant and WT showed comparable growth in LB under different concentration of 
paraquat (Fig 3d). Despite increased expression of PqiB in E. coli K-12 following 
paraquat treatment (2), we were not able to replicate these responses in ETEC H10407, 
suggesting that pqiB of ETEC may respond to different signals. 
Interestingly, we found that PqiB contains a mammalian cell entry (mce) domain first 
identified in Mycobacterium tuberculosis (7) where it facilitates pathogen host-
interaction. Krachler et al. subsequently demonstrated that many Gram negative 
pathogens (8), including Vibrio parahaemolyticus, Vibrio choleare and enteropathogenic 
E. coli (EPEC), possess mce domain containing proteins (9), which they named 
multivalent adhesion molecules (MAM) (9, 10). They demonstrated that MAM7, which 
contain 7 mce domains, functions as an adhesin in V. parahaemolyticus as well as V. 
cholerae (9). EPEC also express MAM7 homologue of Vibrio encoded by yebT, and 
deletion of yebT decreased EPEC E2348/69 adhesion to host cells (9). Interestingly, we 
found that ETEC_1867 gene (pqiB) of ETEC H10407 encodes PqiB, which is 97% 
similar to yebT, and that the respective proteins are 99% similar (Supplementary figure 
1). Therefore, we assumed that PqiB might also facilitate ETEC interaction with host, 
promoting adhesion.  
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Surprisingly, although episomal expression of pqiB of ETEC in E. coli TOP10 increased 
adhesion of TOP10 to Caco-2 human intestinal cells (Fig 4a), an isogenic pqiB ETEC 
mutant was significantly more adherent than WT ETEC to Caco-2 (Fig 4b), as well as to 
other intestinal cell lines (Fig 4c). The explanation for these seemingly contradictory 
adhesion phenotypes is not presently clear. Intriguingly, Nakayama and Zhang-Akiyama 
recently proposed that pqiAB operon encodes a transport pathway and contributes to 
membrane integrity (11), suggesting that it may serve other functions. Alternatively, the 
increased adhesion phenotype of the pqiB mutant could be the result of a compensatory 
increase in one or more other adhesin molecules. Further studies are needed to 
understand the contribution of PqiB, encoded on the core E. coli genome, to ETEC 
pathogenesis.    
4.3 FimH variants 
As the FimH adhesin of type 1 pili mediates interaction with host receptors via the lectin 
domain (12), minor changes to the FimH sequence could affect receptor-ligand 
interactions (13). For instance, variations in FimH sequence provide significant 
advantages to the bacteria during bladder (13, 14) and intestinal colonization (15). The 
mature FimH subunit is folded into two domains connected by 8 amino acid (aa) inter 
domain linker peptide: the N-terminal lectin domain (LD, 1-150 aa), containing the 
mannose binding pocket, and the C-terminal pilin domain (PD, 159-279 aa), interacting 
with the pilus rod to anchor the adhesin at the tip (12, 16-18). The mannose binding 
pocket is located at the top of the lectin domain, opposite the LD-PD interface (17), and 
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is accessible to the terminally exposed mannose sugars of the receptors. The binding 
pocket is comprised of 8 aa residues, including 1Phe, 46Asn, 47Asp, 54Asp, 133Gln, 
135Asn, 140Asp, and 142Phe (16, 17). Changes in any one of these residues may reduce 
or completely abolish mannose binding activity (17). Additionally, interactions between 
the LD and PD domains alter the affinity of the mannose-binding pocket via an allosteric 
mechanism (19, 20). Moreover, multiple studies have shown that interdomain 
interactions of FimH regulate the conformational states- between a high affinity 
elongated state and a low affinity compact state (20-22). Switching between the 
elongated and compact conformations is important for proper binding to the receptor at 
appropriate niches. For instance, in the urinary tract, UPEC occasionally experience 
high shear force which separates the domains, causing the lectin domain to switch from 
a low affinity to a high affinity conformation (19). These high affinity interactions may 
prevent UPEC elimination from its niche. Consequently, changes in either of the 
domains or the linker could play an indirect role in modulating the mannose binding 
activity (23). In fact, mannose binding affinity is greatly enhanced in FimH variants with 
mutations in either the PD or LD which disrupt the interdomain interactions (19, 23, 
24). Additionally, minor changes in FimH alter structural flexibility, allowing functional 
heterogeneity (25, 26).  
Recently, we have sequenced 176 clinical isolates of ETEC recovered from 
symptomatic or asymptomatic fecal specimens (27). To examine the variation in FimH 
adhesins of ETEC, we performed sequence alignment analysis (CLUSTAL Omega, 
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version 1.2.4) of these isolates (table 1) and identified multiple variants of FimH 
(supplementary figure 2) that might impact type 1 pili mediated ETEC interaction with 
the receptor(s). Further studies will be necessary to evaluate the significance of these 
variants in ETEC infection.  
4.4 Concluding remarks 
 
This thesis work set out to better understand the contribution of highly conserved type 1 
pili of ETEC, a genotypically and phenotypically diverse E. coli pathovar, to its 
interactions with intestinal epithelium. While some early studies predicted that type 1 pili 
mediate ETEC adhesion to intestinal epithelia (28, 29), others argued against it (30, 31). 
The findings described in the thesis convincingly demonstrate that type 1 pili of ETEC 
play an essential role in pathogenesis of these diverse bacteria. Additional findings, 
including detection of a novel FimH-CECAM6 mediated ETEC-host interaction, 
identification of the role of conserved PqiB in ETEC for intestinal colonization of mice, 
and detection of changes in glycosylation processes following LT treatment, suggest 
multitude of host responses to ETEC infection. In summary, documentation of role of 
type 1 pili and identification of at least two conserved factors that contribute to ETEC 
pathogenesis expand our understanding of the complex ETEC-host interactions. 
Comprehensive investigations of these emerging interactions could ultimately lead to 
broadly protective vaccine against highly diverse ETEC pathogens.  
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Table 1: FimH variants of ETEC 
    
 
 
Variants 
Number 
of isolates 
(%) 
Mutations at amino acid residues
†
 
Signal 
peptide 
Lectin domain
‡
 Pilin domain
‡
 
6
 
5
 
9
 
2
3
 
2
7
 
6
6
 
6
7
 
6
9
 
1
1
8
 
1
1
9
 
1
6
5
 
1
9
5
 
2
0
2
 
2
1
0
 
2
4
3
 
2
4
8
 
2
6
9
 
Common T T T N A G V S V A A Y A T V V Q 
Common 89 (50.57)                  
Variant #1 11 (6.25) N                 
Variant #2  1 (0.57) N   T              
Variant #3 3 (1.70) N         V        
Variant #4 1 (0.57) N            V     
Variant #5 1 (0.57) S                 
Variant #6 1 (0.57) P                 
Variant #7 1 (0.57)  P               K 
Variant #8 1 (0.57)   A         F      
Variant #9 2 (1.14)     V             
Variant #10 25 (14.20)      S       V     
Variant #11 6 (3.41)       G           
Variant #12 1 (0.57)       G          K 
Variant #13 1 (0.57)        F          
Variant #14 1 (0.57)         G         
Variant #15 1 (0.57)           S       
Variant #16 1 (0.57)            D      
Variant #17 3 (1.70)             V     
Variant #18 11 (6.25)              I    
Variant #19 1 (0.57)               G   
Variant #20 1 (0.57)                G  
Variant #21 13 (7.39)                 K 
Total 176                  
†
Blank entries indicate identity with common variant 
‡
Amino acid number based on mature peptide 
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Figure 1: ETEC pathogenesis model. 
Cartoon depicts emerging complexity of pathogen-host interactions following ETEC infection. ETEC interact with intestinal 
epithelium using multiple adhesion factors, including type 1 pili, for delivery of toxins. Following internalization, LT 
enhances intracellular cAMP, leading to modification of different host pathways, including multiple steps of the 
glycosylation process, resulting in alteration of cell surface glycan landscape that impact ETEC-host interactions. 
Enzymes those are activated in response to LT are marked with asterisks (red). Increased expressions are shown with 
upward arrows (green) and decreased expressions are shown with downward arrows (red).   
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Figure 2: Mouse intestinal colonization by pqiB mutant.  
Plot represents competitive index (CI) between pqiB mutant and WT in fecal shedding, 
acquired from duplicate experiments (left panel). Each dot represents datum from single 
mouse co-infected with pqiB mutant and WT ETEC. Competitive colonization index of 
pqiB mutant with WT in different intestinal niches, including jejunum, ileum and colon 
(right panel). Horizontal lines showing mean with SEM.     
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Figure 3: Detection of PqiB in ETEC and its contribution in growth.  
a) Coomassie staining and anti-Myc immunoblot of PqiB of ETEC H10407 cloned into 
expression vector in fusion with Myc-Histidine tag and expressed in TOP10 E. coli. b) 
Confocal immunofluorescene microscopy images of TOP10 E. coli expressing Myc-His 
tagged PqiB. Signals were detected with affinity purified anti-PqiB antibodies (green) 
and anti-Myc monoclonal antibodies (red); merged image (right) shows co-localization 
of both antibodies. c) Anti-PqiB immunoblot of triton extracts of ETEC H10407 grown in 
different concentrations of paraquat. Triton extract of the pqiB mutant (right) is shown as 
a negative control. d) Growth curves of pqiB mutant and WT E. coli in different 
concentrations of paraquat.      
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Figure 4: Contribution of PqiB in adhesion to intestinal cells. 
a) In vitro adhesion assay of E. coli Top10 to Caco-2 intestinal cells in the absence or 
presence of PqiB of ETEC. Dashed lines represent mean adhesion. P value was 
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calculated by nonparametric Mann-Whitney test. **<0.001. b) Adhesion of isogenic 
H10407, pqiB mutant, complemented pqiB mutant (ppqiB) and vector control pqiB 
mutant ETEC to Caco-2 intestinal cells. Dashed lines represent mean adhesion. P 
values were calculated by nonparametric Mann-Whitney test. **<0.001. c) Adhesion of 
isogenic H10407 and pqiB mutant ETEC to other intestinal cell lines, including C2BBe1 
and T-84 intestinal cells. Dashed lines represent mean adhesion. P values were 
calculated by nonparametric Mann-Whitney test. **<0.001.  
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S1 Figure 1: Sequence alignment of mce domain containing proteins. 
a) Schematic representation of mce domain containing protein (accession: CBJ01372) 
from H10407 (https://www.ncbi.nlm.nih.gov/protein/CBJ01372). mce domains 
(accession: 5UW8_A; https://www.ncbi.nlm.nih.gov/protein/5UW8_A) were identified 
using the domain-enhanced lookup time-accelerated BLAST (DELTA-BLAST). b) Data 
represent multiple sequence alignment of mce domain containing protein from ETEC 
strain H10407, commensal K-12 strain MG1655 (PqiB, NP_416348; 
https://www.ncbi.nlm.nih.gov/protein/NP_416348.2) and EPEC strain E2348/69 (YebT, 
WP_001347086; https://www.ncbi.nlm.nih.gov/protein/WP_001347086.1). Highlighted 
amino acid residues are sequences of multiple mce domains.    
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S2 Figure: Phylogenetic tree analysis of ETEC FimH adhesin. 
FimH sequences were acquired from recently sequenced ETEC clinical isolates (27). 
Phylogenetic tree was generated using iTOL software (http://itol.embl.de).  
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